

Rapid epidemic expansion of the SARS-CoV-2 Omicron

Nature

603, 679-686

DOI: [10.1038/s41586-022-04411-y](https://doi.org/10.1038/s41586-022-04411-y)

Citation Report

#	ARTICLE	IF	CITATIONS
9	Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. <i>Nature</i> , 2022, 602, 671-675.	13.7	1,202
10	Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination Boosts Neutralizing Activity Against Seasonal Human Coronaviruses. <i>Clinical Infectious Diseases</i> , 2022, 75, e653-e661.	2.9	16
11	Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. <i>Lancet, The</i> , 2022, 399, 437-446.	6.3	818
12	Prisoners of variants, or free to act as prisoners of swabs? The case of Italy. <i>Journal of Medical Virology</i> , 2022, 94, 2334-2335.	2.5	1
13	Where did Omicron come from? Three key theories. <i>Nature</i> , 2022, 602, 26-28.	13.7	118
15	T cell responses to SARS-CoV-2 spike cross-recognize Omicron. <i>Nature</i> , 2022, 603, 488-492.	13.7	430
16	Genomic Perspectives on the Emerging SARS-CoV-2 Omicron Variant. <i>Genomics, Proteomics and Bioinformatics</i> , 2022, 20, 60-69.	3.0	46
18	Omicron neutralising antibodies after COVID-19 vaccination in haemodialysis patients. <i>Lancet, The</i> , 2022, 399, 800-802.	6.3	35
19	The Emergence of SARS-CoV-2 Variants of Concern Is Driven by Acceleration of the Substitution Rate. <i>Molecular Biology and Evolution</i> , 2022, 39, .	3.5	78
20	SARS-CoV-2 Transmission and Prevention in the Era of the Delta Variant. <i>Infectious Disease Clinics of North America</i> , 2022, 36, 267-293.	1.9	10
21	Challenges in Inferring Intrinsic Severity of the SARS-CoV-2 Omicron Variant. <i>New England Journal of Medicine</i> , 2022, 386, e14.	13.9	124
22	T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals. <i>Cell</i> , 2022, 185, 1041-1051.e6.	13.5	187
23	SARS-CoV-2 variants preferentially emerge at intrinsically disordered protein sites helping immune evasion. <i>FEBS Journal</i> , 2022, 289, 4240-4250.	2.2	25
24	Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. <i>Nature</i> , 2022, 603, 706-714.	13.7	756
25	Emergence of a recurrent insertion in the N-terminal domain of the SARS-CoV-2 spike glycoprotein. <i>Virus Research</i> , 2022, 310, 198674.	1.1	24
26	Decreased severity of disease during the first global omicron variant covid-19 outbreak in a large hospital in tshwane, south africa. <i>International Journal of Infectious Diseases</i> , 2022, 116, 38-42.	1.5	301
27	Ad26.COVS breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS-CoV-2 variants of concern. <i>Cell Reports Medicine</i> , 2022, 3, 100535.	3.3	31
30	SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-week interval between doses. <i>Cell Reports</i> , 2022, 38, 110429.	2.9	50

#	ARTICLE	IF	CITATIONS
32	Signals of Significantly Increased Vaccine Breakthrough, Decreased Hospitalization Rates, and Less Severe Disease in Patients with Coronavirus Disease 2019 Caused by the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2 in Houston, Texas. <i>American Journal of Pathology</i> , 2022, 192, 642-652.	1.9	161
34	Development and evaluation of an RT-qPCR for the identification of the SARS-CoV-2 Omicron variant. <i>Journal of Clinical Virology</i> , 2022, 148, 105101.	1.6	10
35	New year, new SARS-CoV-2 variant: Resolutions on genomic surveillance protocols to face Omicron. <i>The Lancet Regional Health Americas</i> , 2022, 7, 100203.	1.5	3
36	Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. <i>Nature</i> , 0, , .	13.7	104
37	Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. <i>Nature</i> , 0, , .	13.7	88
38	Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. <i>Nature</i> , 2022, 602, 654-656.	13.7	928
39	Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement. <i>Science</i> , 2022, 375, 864-868.	6.0	394
40	Replacement of the Gamma by the Delta variant in Brazil: Impact of lineage displacement on the ongoing pandemic. <i>Virus Evolution</i> , 2022, 8, veac024.	2.2	37
41	Towards SARS-CoV-2 serotypes?. <i>Nature Reviews Microbiology</i> , 2022, 20, 187-188.	13.6	81
42	Paediatric hospitalisations due to COVID-19 during the first SARS-CoV-2 omicron (B.1.1.529) variant wave in South Africa: a multicentre observational study. <i>The Lancet Child and Adolescent Health</i> , 2022, 6, 294-302.	2.7	141
43	Spread of Gamma (P.1) Sub-Lineages Carrying Spike Mutations Close to the Furin Cleavage Site and Deletions in the N-Terminal Domain Drives Ongoing Transmission of SARS-CoV-2 in Amazonas, Brazil. <i>Microbiology Spectrum</i> , 2022, 10, e0236621.	1.2	28
45	Forecast of Omicron Wave Time Evolution. <i>Covid</i> , 2022, 2, 216-229.	0.7	6
46	Nasal delivery of broadly neutralizing antibodies protects mice from lethal challenge with SARS-CoV-2 delta and omicron variants. <i>Virologica Sinica</i> , 2022, 37, 238-247.	1.2	17
47	What Is New With Omicron Variant of SARS-CoV-2 in Children?. <i>Journal of Clinical Medicine Research</i> , 2022, 14, 108-109.	0.6	3
55	Structural and antigenic variations in the spike protein of emerging SARS-CoV-2 variants. <i>PLoS Pathogens</i> , 2022, 18, e1010260.	2.1	81
57	Nonself Mutations in the Spike Protein Suggest an Increase in the Antigenicity and a Decrease in the Virulence of the Omicron Variant of SARS-CoV-2. <i>Covid</i> , 2022, 2, 407-418.	0.7	3
59	Structural Dynamics and Molecular Evolution of the SARS-CoV-2 Spike Protein. <i>MBio</i> , 2022, 13, e0203021.	1.8	10
60	Three doses of BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 Omicron variant. <i>Npj Vaccines</i> , 2022, 7, 35.	2.9	34

#	ARTICLE	IF	CITATIONS
61	Antibody evasion properties of SARS-CoV-2 Omicron sublineages. <i>Nature</i> , 2022, 604, 553-556.	13.7	649
62	The changing epidemiology of SARS-CoV-2. <i>Science</i> , 2022, 375, 1116-1121.	6.0	177
63	Sisonke: reaching several goals together. <i>Lancet, The</i> , 2022, 399, 1095-1097.	6.3	1
64	Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Subvariant BA.2 in a Single-Source Community Outbreak. <i>Clinical Infectious Diseases</i> , 2022, 75, e44-e49.	2.9	66
66	Molecular epidemiology of the SARS-CoV-2 variant Omicron BA.2 sub-lineage in Denmark, 29 November 2021 to 2 January 2022. <i>Eurosurveillance</i> , 2022, 27, .	3.9	70
67	In vitro evaluation of therapeutic antibodies against a SARS-CoV-2 Omicron B.1.1.529 isolate. <i>Scientific Reports</i> , 2022, 12, 4683.	1.6	33
68	Organoid Models of SARS-CoV-2 Infection: What Have We Learned about COVID-19?. <i>Organoids</i> , 2022, 1, 2-27.	1.8	12
69	SARS-CoV-2 Evolution: On the Sudden Appearance of the Omicron Variant. <i>Journal of Virology</i> , 2022, 96, e0009022.	1.5	32
70	SARS-CoV-2: tracing the origin, tracking the evolution. <i>BMC Medical Genomics</i> , 2022, 15, 62.	0.7	17
71	SARS-CoV-2 Omicron Symptomatic Infections in Previously Infected or Vaccinated South African Healthcare Workers. <i>Vaccines</i> , 2022, 10, 459.	2.1	24
72	Fatal SARS-CoV-2 Omicron variant in a young infant: Autopsy findings. <i>Pediatric Pulmonology</i> , 2022, 57, 1363-1365.	1.0	11
73	Fusogenicity and neutralization sensitivity of the SARS-CoV-2 Delta sublineage AY.4.2. <i>EBioMedicine</i> , 2022, 77, 103934.	2.7	10
74	Can Maintaining Optimal Magnesium Balance Reduce the Disease Severity of COVID-19 Patients?. <i>Frontiers in Endocrinology</i> , 2022, 13, 843152.	1.5	11
75	Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study. <i>Lancet Infectious Diseases, The</i> , 2022, 22, 813-820.	4.6	64
79	Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection. <i>Science Translational Medicine</i> , 2022, 14, eabn8057.	5.8	150
80	Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa. <i>Science</i> , 2022, 376, eabn4947.	6.0	651
81	mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron. <i>Cell</i> , 2022, 185, 1556-1571.e18.	13.5	179
83	Selection Analysis Identifies Clusters of Unusual Mutational Changes in Omicron Lineage BA.1 That Likely Impact Spike Function. <i>Molecular Biology and Evolution</i> , 2022, 39, .	3.5	84

#	ARTICLE	IF	CITATIONS
84	Global trends in COVID-19. , 2022, 1, 31-39.		8
86	Can the SARS-CoV-2 Omicron Variant Confer Natural Immunity against COVID-19?. <i>Molecules</i> , 2022, 27, 2221.	1.7	12
87	Functional analysis of polymorphisms at the S1/S2 site of SARS-CoV-2 spike protein. <i>PLoS ONE</i> , 2022, 17, e0265453.	1.1	8
88	Relative contagiousness of emerging virus variants: An analysis of the Alpha, Delta, and Omicron SARS-CoV-2 variants. <i>Econometrics Journal</i> , 2022, 25, 739-761.	1.2	12
89	Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. <i>BMJ</i> , The, 2022, 376, e069761.	3.0	393
90	Rapid and parallel adaptive mutations in spike S1 drive clade success in SARS-CoV-2. <i>Cell Host and Microbe</i> , 2022, 30, 545-555.e4.	5.1	59
92	Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies. <i>Nature Medicine</i> , 2022, 28, 1297-1302.	15.2	235
93	SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals. <i>Cell Host and Microbe</i> , 2022, 30, 880-886.e4.	5.1	80
95	High-Integrity Sequencing of Spike Gene for SARS-CoV-2 Variant Determination. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3257.	1.8	4
97	Clinical Significance of COVID-19 and Diabetes: In the Pandemic Situation of SARS-CoV-2 Variants including Omicron (B.1.1.529). <i>Biology</i> , 2022, 11, 400.	1.3	10
98	Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants. <i>New England Journal of Medicine</i> , 2022, 386, 1579-1580.	13.9	296
99	Omicron: fewer adverse outcomes come with new dangers. <i>Lancet</i> , The, 2022, 399, 1280-1281.	6.3	17
100	Unlocking capacities of genomics for the COVID-19 response and future pandemics. <i>Nature Methods</i> , 2022, 19, 374-380.	9.0	35
102	Omicron "Decoupling Infection from Severe Disease. <i>New England Journal of Medicine</i> , 2022, 386, 1361-1362.	13.9	7
104	Emergence and phenotypic characterization of the global SARS-CoV-2 C.1.2 lineage. <i>Nature Communications</i> , 2022, 13, 1976.	5.8	27
105	Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine. <i>Cell</i> , 2022, 185, 1875-1887.e8.	13.5	148
106	Rapid emergence of SARS-CoV-2 Omicron variant is associated with an infection advantage over Delta in vaccinated persons. <i>Med</i> , 2022, 3, 325-334.e4.	2.2	60
107	Early Emergence Phase of SARS-CoV-2 Delta Variant in Florida, US. <i>Viruses</i> , 2022, 14, 766.	1.5	1

#	ARTICLE	IF	CITATIONS
108	An assessment of the potential impact of the Omicron variant of SARS-CoV-2 in Aotearoa New Zealand. <i>Infectious Disease Modelling</i> , 2022, 7, 94-105.	1.2	12
110	SARS-CoV-2-specific immune responses in boosted vaccine recipients with breakthrough infections during the Omicron variant surge. <i>JCI Insight</i> , 2022, 7, .	2.3	15
111	Amplification Artifact in SARS-CoV-2 Omicron Sequences Carrying P681R Mutation, New York, USA. <i>Emerging Infectious Diseases</i> , 2022, 28, 881-883.	2.0	6
112	Assessing the clinical severity of the Omicron variant in the Western Cape Province, South Africa, using the diagnostic PCR proxy marker of RdRp target delay to distinguish between Omicron and Delta infections – a survival analysis. <i>International Journal of Infectious Diseases</i> , 2022, 118, 150-154.	1.5	22
113	Two SARS-CoV-2 serology assays detect antibodies in the sera of individuals diagnosed with SARS-CoV-2 Omicron variant. <i>Clinical Biochemistry</i> , 2022, 103, 35-36.	0.8	0
114	Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges. <i>Metabolism Open</i> , 2022, 14, 100180.	1.4	41
115	Detection of the Omicron variant of SARS-CoV-2 in international travelers returning to Venezuela. <i>Travel Medicine and Infectious Disease</i> , 2022, 48, 102326.	1.5	4
119	Structures of Omicron spike complexes and implications for neutralizing antibody development. <i>Cell Reports</i> , 2022, 39, 110770.	2.9	47
120	Research progress on vaccine efficacy against SARS-CoV-2 variants of concern. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-12.	1.4	10
121	Identification of SARS-CoV-2 Omicron variant using spike gene target failure and genotyping assays, Gauteng, South Africa, 2021. <i>Journal of Medical Virology</i> , 2022, 94, 3676-3684.	2.5	23
122	COVID-19 severity from Omicron and Delta SARS-CoV-2 variants. <i>Influenza and Other Respiratory Viruses</i> , 2022, 16, 832-836.	1.5	60
123	A SARS-CoV-2 omicron (B.1.1.529) variant outbreak in a primary school in Geneva, Switzerland. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 767-768.	4.6	16
124	Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province, South Africa. <i>Tropical Medicine and International Health</i> , 2022, 27, 564-573.	1.0	94
125	Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants. <i>Med</i> , 2022, 3, 422-432.e3.	2.2	9
127	Expanded COVID-19 phenotype definitions reveal distinct patterns of genetic association and protective effects. <i>Nature Genetics</i> , 2022, 54, 374-381.	9.4	48
129	Research priorities to reduce the impact of COVID-19 in low- and middle-income countries. <i>Journal of Global Health</i> , 2022, 12, 09003.	1.2	15
130	Structural and functional impact by SARS-CoV-2 Omicron spike mutations. <i>Cell Reports</i> , 2022, 39, 110729.	2.9	102
132	Evaluating the risk factor of novel public health disaster – Omicron variant: an Indian prospective. <i>Modeling Earth Systems and Environment</i> , 2022, , 1-6.	1.9	0

#	ARTICLE	IF	CITATIONS
133	New Variants in SARS-CoV-2: What are we Learning from the Omicron Variant?. Archivos De Bronconeumologia, 2022, 58, 3-5.	0.4	2
134	Properties of the Omicron Variant of SARS-CoV-2 Affect Public Health Measure Effectiveness in the COVID-19 Epidemic. International Journal of Environmental Research and Public Health, 2022, 19, 4930.	1.2	6
136	COVID-19: Omicron – the latest, the least virulent, but probably not the last variant of concern of SARS-CoV-2. Microbial Biotechnology, 2022, 15, 1927-1939.	2.0	41
137	Delta Infection After Vaccination Elicits Potent Neutralizing Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron. Journal of Infectious Diseases, 2022, 226, 1551-1555.	1.9	4
138	Humoral and cellular responses to spike of the SARS-CoV-2 variant in vaccinated patients with immune-mediated inflammatory diseases. International Journal of Infectious Diseases, 2022, 121, 24-30.	1.5	21
139	Immunogenicity of BNT162b2 vaccine booster against SARS-CoV-2 Delta and Omicron variants in nursing home residents: A prospective observational study in older adults aged from 68 to 98 years. Lancet Regional Health - Europe, The, 2022, 17, 100385.	3.0	18
140	SARS-CoV-2 epidemic in Brazil: how the displacement of variants has driven distinct epidemic waves. Virus Research, 2022, 315, 198785.	1.1	26
141	Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design. Lancet Infectious Diseases, The, 2022, 22, 959-966.	4.6	202
142	Sustainability of surveillance systems for SARS-CoV-2. Lancet Infectious Diseases, The, 2022, 22, 914-915.	4.6	5
143	Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case-control study. Lancet Respiratory Medicine, the, 2022, 10, 689-699.	5.2	108
145	Genomic and epidemiological report of the recombinant XJ lineage SARS-CoV-2 variant, detected in northern Finland, January 2022. Eurosurveillance, 2022, 27, .	3.9	10
146	Introduction and Rapid Spread of SARS-CoV-2 Omicron Variant and Dynamics of BA.1 and BA.1.1 Sublineages, Finland, December 2021. Emerging Infectious Diseases, 2022, 28, .	2.0	13
147	SARS-CoV-2: Evolution and Emergence of New Viral Variants. Viruses, 2022, 14, 653.	1.5	39
148	Safety and Cross-Reactive Immune Response Against the Omicron Variant of a Third Dose of CoronaVac, and Immune Persistence of Primary Immunization in Healthy Children and Adolescents: Interim Results from a Double-Blind, Randomised, Placebo-Controlled Phase 2 Clinical Trial. SSRN Electronic Journal, 0, .	0.4	0
149	Overlapping Delta and Omicron Outbreaks During the COVID-19 Pandemic: Dynamic Panel Data Estimates. JMIR Public Health and Surveillance, 2022, 8, e37377.	1.2	2
151	Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants. BioDrugs, 2022, 36, 231-323.	2.2	24
154	Enhanced BNT162b2 vaccine-induced cellular immunity in anti-CD19 CAR T cell-treated patients. Blood, 2022, 140, 156-160.	0.6	10
155	Considerations for the Feasibility of Neutralizing Antibodies as a Surrogate Endpoint for COVID-19 Vaccines. Frontiers in Immunology, 2022, 13, 814365.	2.2	10

#	ARTICLE	IF	CITATIONS
156	Effectiveness of Messenger RNA-based Vaccines During the Emergence of the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant. <i>Clinical Infectious Diseases</i> , 2022, 75, 2186-2192.	2.9	12
157	Delays in the arrival of the waves of COVID-19: a comparison between Gabon and the African continent. <i>Lancet Microbe</i> , The, 2022, 3, e476.	3.4	2
159	SARS-CoV-2 Omicron Variant: Epidemiological Features, Biological Characteristics, and Clinical Significance. <i>Frontiers in Immunology</i> , 2022, 13, 877101.	2.2	74
160	Binding Interactions between Receptor-Binding Domain of Spike Protein and Human Angiotensin Converting Enzyme-2 in Omicron Variant. <i>Journal of Physical Chemistry Letters</i> , 2022, 13, 3915-3921.	2.1	49
161	Genetic differentiation and diversity of SARS-CoV-2 Omicron variant in its early outbreak. <i>Biosafety and Health</i> , 2022, 4, 171-178.	1.2	11
162	Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2. <i>Cell</i> , 2022, 185, 2265-2278.e14.	13.5	77
163	SARS-CoV-2 Transmission Control Measures in the Emergency Department: The Role of Rapid Antigenic Testing in Asymptomatic Subjects. <i>Healthcare (Switzerland)</i> , 2022, 10, 790.	1.0	2
164	Probing the Immune System Dynamics of the COVID-19 Disease for Vaccine Designing and Drug Repurposing Using Bioinformatics Tools. <i>Immuno</i> , 2022, 2, 344-371.	0.6	2
165	Clinical Profile and Outcome of Hospitalized Confirmed Cases of Omicron Variant of SARS-CoV-2 Among Children in Pune, India. <i>Cureus</i> , 2022, , .	0.2	4
166	Relative Vaccine Effectiveness of a Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccine Booster Dose Against the Omicron Variant. <i>Clinical Infectious Diseases</i> , 2022, 75, 2161-2168.	2.9	35
169	Identification of Omicron-Delta Coinfections Using PCR-Based Genotyping. <i>Microbiology Spectrum</i> , 2022, 10, e0060522.	1.2	6
170	Favorable vaccine-induced SARS-CoV-2-specific T cell response profile in patients undergoing immune-modifying therapies. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	20
171	SARS-CoV-2 variants Evolution, spike protein, and vaccines. <i>Biomedical Journal</i> , 2022, 45, 573-579.	1.4	26
172	African Genetic Representation in the Context of SARS-CoV-2 Infection and COVID-19 Severity. <i>Frontiers in Genetics</i> , 2022, 13, .	1.1	5
173	Neutralizing Antibodies Against the SARS-CoV-2 Omicron Variant (BA.1) 1 to 18 Weeks After the Second and Third Doses of the BNT162b2 mRNA Vaccine. <i>JAMA Network Open</i> , 2022, 5, e2212073.	2.8	40
174	Skewed Cellular Distribution and Low Activation of Functional T-Cell Responses in SARS-CoV-2 Non-Seroconvertors. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	2
175	Omicron Variant in the Critical Care Units of the Paris Metropolitan Area: The Reality Research Group. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 349-363.	2.5	19
176	Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike. <i>Cell</i> , 2022, 185, 2103-2115.e19.	13.5	273

#	ARTICLE	IF	CITATIONS
177	Tâ€cell responses to SARSâ€CoVâ€2 Omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine. <i>Journal of Medical Virology</i> , 2022, 94, 3998-4004.	2.5	20
178	Pathogenicity of SARSâ€CoVâ€2 Omicron. <i>Clinical and Translational Medicine</i> , 2022, 12, e880.	1.7	12
179	A fourth dose of Omicron RBD vaccine enhances broad neutralization against SARSâ€CoVâ€2 variants including BA.1 and BA.2 in vaccinated mice. <i>Journal of Medical Virology</i> , 2022, , .	2.5	5
181	Instructing durable humoral immunity for COVID-19 and other vaccinable diseases. <i>Immunity</i> , 2022, 55, 945-964.	6.6	32
182	Conducting the RBD of SARS-CoV-2 Omicron Variant with Phytoconstituents from <i>Euphorbia dendroides</i> to Repudiate the Binding of Spike Glycoprotein Using Computational Molecular Search and Simulation Approach. <i>Molecules</i> , 2022, 27, 2929.	1.7	2
183	Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages. <i>Cell Host and Microbe</i> , 2022, 30, 1077-1083.e4.	5.1	132
185	Omicron: increased transmissibility and decreased pathogenicity. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 151.	7.1	99
186	Novel fold of rotavirus glycan-binding domain predicted by AlphaFold2 and determined by X-ray crystallography. <i>Communications Biology</i> , 2022, 5, 419.	2.0	10
188	Modeling transmission of SARS-CoV-2 Omicron in China. <i>Nature Medicine</i> , 2022, 28, 1468-1475.	15.2	177
189	Understanding the omicron variant (B.1.1.529) of SARS-CoV-2: Mutational impacts, concerns, and the possible solutions. <i>Annals of Medicine and Surgery</i> , 2022, 78, 103737.	0.5	33
190	Pathogenicity of SARS-CoV-2 Omicron BA.1.1 in hamsters. <i>EBioMedicine</i> , 2022, 80, 104035.	2.7	4
191	Spherical neutralizing aptamer suppresses SARS-CoV-2 Omicron escape. <i>Nano Today</i> , 2022, 44, 101499.	6.2	23
192	Improved oral detection is a characteristic of Omicron infection and has implications for clinical sampling and tissue tropism. <i>Journal of Clinical Virology</i> , 2022, 152, 105170.	1.6	18
193	Investigating expressed RNA variants that are related to disease severity in SARS-CoV-2-infected patients with mild-to-severe disease. <i>Egyptian Journal of Medical Human Genetics</i> , 2022, 23, .	0.5	1
194	Clinical features and predictive factors related to liver injury in SARS-CoV-2 Delta and Omicron variant-infected patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, 34, 933-939.	0.8	19
195	Antibody-mediated neutralization of SARS-CoV-2. <i>Immunity</i> , 2022, 55, 925-944.	6.6	74
196	Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant. <i>Nature Communications</i> , 2022, 13, 2670.	5.8	108
197	The emergence of SARS-CoV-2 variants of concern in Australia by haplotype coalescence reveals a continental link to COVID-19 seasonality. <i>Methods in Microbiology</i> , 2022, , 233-268.	0.4	2

#	ARTICLE	IF	CITATIONS
199	Efficient antibody evasion but reduced ACE2 binding by the emerging SARS-CoV-2 variant B.1.640.2. , 2022, , .		0
200	Convolutional Neural Networks Based on Sequential Spike Predict the High Human Adaptation of SARS-CoV-2 Omicron Variants. <i>Viruses</i> , 2022, 14, 1072.	1.5	3
201	Routine Surveillance and Vaccination on a University Campus During the Spread of the SARS-CoV-2 Omicron Variant. <i>JAMA Network Open</i> , 2022, 5, e2212906.	2.8	8
202	A Class of Sharkâ€Derived Singleâ€Domain Antibodies can Broadly Neutralize SARSâ€Related Coronaviruses and the Structural Basis of Neutralization and Omicron Escape. <i>Small Methods</i> , 2022, 6, e2200387.	4.6	14
203	Proteomic characterization of Omicron SARS-CoV-2 host response. <i>Cell Discovery</i> , 2022, 8, 46.	3.1	8
204	PARIS and SPARTA: Finding the Achillesâ€™ Heel of SARS-CoV-2. <i>MSphere</i> , 2022, 7, e0017922.	1.3	25
205	Human Identical Sequences, hyaluronan, and hymecromone â”€ the newÂmechanism and management of COVID-19. <i>Molecular Biomedicine</i> , 2022, 3, 15.	1.7	4
211	Regional Replacement of SARS-CoV-2 Variant Omicron BA.1 with BA.2 as Observed through Wastewater Surveillance. <i>Environmental Science and Technology Letters</i> , 2022, 9, 575-580.	3.9	23
212	Omicron variant of SARS-CoV-2 exhibits an increased resilience to the antiviral type I interferon response. , 2022, 1, .		16
214	Analysis of 6.4 million SARS-CoV-2 genomes identifies mutations associated with fitness. <i>Science</i> , 2022, 376, 1327-1332.	6.0	172
216	Evolving strategy for an evolving virus: Development of real-time PCR assays for detecting all SARS-CoV-2 variants of concern. <i>Journal of Virological Methods</i> , 2022, 307, 114553.	1.0	9
219	Therapeutic monoclonal antibodies for COVID-19 management: an update. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 763-780.	1.4	40
220	A bivalent vaccine containing D614G and BA.1 spike trimer proteins or a BA.1 spike trimer protein booster shows broad neutralizing immunity. <i>Journal of Medical Virology</i> , 2022, 94, 4287-4293.	2.5	13
221	Infectious diseases science in Africa takes a leading place in the world. <i>Lancet, The</i> , 2022, , .	6.3	1
222	Experimental Infection of Mink with SARS-COV-2 Omicron Variant and Subsequent Clinical Disease. <i>Emerging Infectious Diseases</i> , 2022, 28, .	2.0	11
223	COVID-19 vaccine booster dose needed to achieve Omicron-specific neutralisation in nursing home residents. <i>EBioMedicine</i> , 2022, 80, 104066.	2.7	30
224	Clinical severity of COVID-19 in patients admitted to hospital during the omicron wave in South Africa: a retrospective observational study. <i>The Lancet Global Health</i> , 2022, 10, e961-e969.	2.9	120
226	Analyzing and Modeling the Spread of SARS-CoV-2 Omicron Lineages BA.1 and BA.2, France, September 2021â€February 2022. <i>Emerging Infectious Diseases</i> , 2022, 28, 1355-1365.	2.0	18

#	ARTICLE	IF	CITATIONS
227	Replication of SARS-CoV-2 Omicron BA.2 Variant in <i>Ex Vivo</i> Cultures of the Human Upper and Lower Respiratory Tract. SSRN Electronic Journal, 0, , .	0.4	1
228	Simplified Cas13-based assays for the fast identification of SARS-CoV-2 and its variants. Nature Biomedical Engineering, 2022, 6, 932-943.	11.6	76
230	Analysis of seven SARS-CoV-2 rapid antigen tests in detecting omicron (B.1.1.529) versus delta (B.1.617.2) using cell culture supernatants and clinical specimens. Infection, 2023, 51, 239-245.	2.3	4
231	Quantitative Computed Tomography Parameters in Coronavirus Disease 2019 Patients and Prediction of Respiratory Outcomes Using a Decision Tree. Frontiers in Medicine, 0, 9, .	1.2	1
232	Recombination in Positive-Strand RNA Viruses. Frontiers in Microbiology, 2022, 13, .	1.5	12
233	Competition for dominance within replicating quasispecies during prolonged SARS-CoV-2 infection in an immunocompromised host. Virus Evolution, 2022, 8, .	2.2	21
234	Leveraging South African <sc>HIV</sc> research to define <sc>SARSâ€CoV</sc>â€2 immunity triggered by sequential variants of concern. Immunological Reviews, 2022, 310, 61-75.	2.8	6
236	Local genomic sequencing enhances COVID-19 surveillance in the Northern Territory of Australia. Pathology, 2022, 54, 659-662.	0.3	5
238	Omicron Infection Evokes Cross-Protection against SARS-CoV-2 Variants in Vaccinees. Vaccines, 2022, 10, 808.	2.1	7
239	SARS-CoV-2 transmission, persistence of immunity, and estimates of Omicronâ€™s impact in South African population cohorts. Science Translational Medicine, 2022, 14, .	5.8	36
240	An early warning system for emerging SARS-CoV-2 variants. Nature Medicine, 2022, 28, 1110-1115.	15.2	47
243	Could a Lower Toll-like Receptor (TLR) and NF-Î³B Activation Due to a Changed Charge Distribution in the Spike Protein Be the Reason for the Lower Pathogenicity of Omicron?. International Journal of Molecular Sciences, 2022, 23, 5966.	1.8	9
244	SARSâ€CoVâ€2 Spike Stem Protein Nanoparticles Elicited Broad ADCC and Robust Neutralization against Variants in Mice. Small, 2022, 18, .	5.2	11
245	Recent insights into SARSâ€CoVâ€2 omicron variant. Reviews in Medical Virology, 2023, 33, .	3.9	29
246	Increased Frequency of Indels in Hypervariable Regions of SARS-CoV-2 Proteinsâ€”A Possible Signature of Adaptive Selection. Frontiers in Genetics, 0, 13, .	1.1	7
247	SARS-CoV-2 Omicron variants BA.1 and BA.2 both show similarly reduced disease severity of COVID-19 compared to Delta, Germany, 2021 to 2022. Eurosurveillance, 2022, 27, .	3.9	51
248	Evaluation of the Panbio COVID-19 Antigen Rapid Diagnostic Test in Subjects Infected with Omicron Using Different Specimens. Microbiology Spectrum, 2022, 10, .	1.2	17
250	Untangling the changing impact of non-pharmaceutical interventions and vaccination on European COVID-19 trajectories. Nature Communications, 2022, 13, .	5.8	59

#	ARTICLE	IF	CITATIONS
251	SARS-CoV-2 Continuous Genetic Divergence and Changes in Multiplex RT-PCR Detection Pattern on Positive Retesting Median 150 Days after Initial Infection. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6254.	1.8	1
252	Structural Characterization of a Neutralizing Nanobody With Broad Activity Against SARS-CoV-2 Variants. <i>Frontiers in Microbiology</i> , 2022, 13, .	1.5	5
253	Development of a Rapid Live SARS-CoV-2 Neutralization Assay Based on a qPCR Readout. <i>Journal of Clinical Microbiology</i> , 2022, 60, .	1.8	4
254	Limited Cross-Variant Immune Response From SARS-CoV-2 Omicron BA.2 in Naïve But Not Previously Infected Outpatients. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
255	The Effects of Vaccination on the Disease Severity and Factors for Viral Clearance and Hospitalization in Omicron-Infected Patients: A Retrospective Observational Cohort Study from Recent Regional Outbreaks in China. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
256	COVID-19 Vaccine Booster Significantly Decreases the Risk of Intensive Care Unit Hospitalization in Heart Failure Patients During the Omicron Variant Wave: A Population-Based Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
257	BNT162b2 Booster Vaccination Elicits Cross-Reactive Immunity Against SARS-CoV-2 Variants B.1.1.529 and B.1.617.2 in Convalescents of All Ages. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
258	Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5. <i>New England Journal of Medicine</i> , 2022, 387, 86-88.	13.9	433
259	An intranasally administrated SARS-CoV-2 beta variant subunit booster vaccine prevents beta variant replication in rhesus macaques. , 2022, 1, .		10
260	Decline in antibody responses to SARS-CoV-2 post-vaccination poses a risk to health care workers. <i>Journal of Infection</i> , 2022, , .	1.7	4
262	High Neutralizing Antibody Levels Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1 and BA.2 After UB-612 Vaccine Booster. <i>Journal of Infectious Diseases</i> , 2022, 226, 1401-1406.	1.9	18
264	Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant. <i>Clinical Microbiology Reviews</i> , 2022, 35, .	5.7	35
265	Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccinees. <i>Nature Communications</i> , 2022, 13, .	5.8	20
266	T cell epitopes are largely conserved in the SARS-CoV-2 Omicron subvariant (BA.1, BA.2, BA.3, and GKA). <i>Journal of Medical Virology</i> , 2022, 94, 4591-4592.	2.5	5
267	The past, current and future epidemiological dynamic of SARS-CoV-2. <i>Oxford Open Immunology</i> , 2022, 3, .	1.2	24
269	Explosive outbreak of SARS-CoV-2 Omicron variant is associated with vertical transmission in high-rise residential buildings in Hong Kong. <i>Building and Environment</i> , 2022, 221, 109323.	3.0	13
270	Comprehensive Humoral and Cellular Immune Responses to SARS-CoV-2 Variants in Diverse Chinese Population. <i>Research</i> , 2022, 2022, .	2.8	5
272	The Potential of Purinergic Signaling to Thwart Viruses Including SARS-CoV-2. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3

#	ARTICLE	IF	CITATIONS
273	Lessons from SARS-CoV-2 in India: A data-driven framework for pandemic resilience. <i>Science Advances</i> , 2022, 8, .	4.7	16
274	Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2. <i>Nature Communications</i> , 2022, 13, .	5.8	40
275	US County-level COVID-19 Vaccine Uptake and Rates of Omicron Cases and Deaths. <i>Open Forum Infectious Diseases</i> , 0, , .	0.4	1
276	Vaccination and Transmission Risk during the Outbreak of B.1.1.529 (Omicron). <i>Vaccines</i> , 2022, 10, 1003.	2.1	2
277	Evaluation of a commercial SARS-CoV-2 multiplex PCR genotyping assay for variant identification in resource-scarce settings. <i>PLoS ONE</i> , 2022, 17, e0269071.	1.1	11
279	Development of a simple genotyping method based on indel mutations to rapidly screen SARS-CoV-2 circulating variants: Delta, Omicron BA.1 and BA.2. <i>Journal of Virological Methods</i> , 2022, 307, 114570.	1.0	8
280	Cryo-EM structures of SARS-CoV-2 Omicron BA.2 spike. <i>Cell Reports</i> , 2022, 39, 111009.	2.9	74
281	Potential intervariant and intravariant recombination of Delta and Omicron variants. <i>Journal of Medical Virology</i> , 2022, 94, 4830-4838.	2.5	20
283	The Awesome Power of Human Genetics of Infectious Disease. <i>Annual Review of Genetics</i> , 2022, 56, 41-62.	3.2	5
285	Concerns on the Effectiveness of Current COVID-19 Vaccines. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	0
286	Molecular aspects of Omicron, vaccine development, and recombinant strain XE: A review. <i>Journal of Medical Virology</i> , 2022, 94, 4628-4643.	2.5	17
288	Transmission of B.1.617.2 Delta variant between vaccinated healthcare workers. <i>Scientific Reports</i> , 2022, 12, .	1.6	9
292	SARS-CoV-2 Omicron: Light at the End of the Long Pandemic Tunnel or Another False Dawn for Immunodeficient Patients?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 2267-2273.	2.0	10
294	Modeling the Effectiveness of Healthcare Personnel Reactive Testing and Screening for the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Variant Within Nursing Homes. <i>Clinical Infectious Diseases</i> , 2022, 75, S225-S230.	2.9	4
295	SARS-CoV-2 the ASIA virus (Autoimmune/autoinflammatory Syndrome Induced by Adjuvants), the risk of infertility and vaccine hesitancy. <i>Expert Review of Vaccines</i> , 2022, 21, 1177-1184.	2.0	6
296	Effectiveness of Vaccination Against SARS-CoV-2 Omicron Variant Infection, Symptomatic Disease, and Hospitalisation: A Systematic Review and Meta-Analysis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
297	BNT162b2 Effectiveness and Durability Against BA.1 and BA.2 Hospital and Emergency Department Admissions in a Large US Health System: A Test-Negative Design. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
298	How serious is the Omicron variant? transmissibility, genomics, and responses to COVID-19 vaccines, and â€Stealthâ€™ Omicron variants. , 0, 2, .		4

#	ARTICLE	IF	CITATIONS
299	SARS-CoV-2 B.1.1.529 (Omicron) Variant Causes an Unprecedented Surge in Children Hospitalizations and Distinct Clinical Presentation Compared to the SARS-CoV-2 B.1.617.2 (Delta) Variant. <i>Frontiers in Pediatrics</i> , 0, 10, .	0.9	14
302	Droplet nuclei is generated during the colonoscopy and is decreased by the use of carbon dioxide and water immersion technique. <i>Digestive Endoscopy</i> , 0, , .	1.3	1
303	Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa. <i>Nature Medicine</i> , 2022, 28, 1785-1790.	15.2	456
304	Projecting the SARS-CoV-2 transition from pandemicity to endemicity: Epidemiological and immunological considerations. <i>PLoS Pathogens</i> , 2022, 18, e1010591.	2.1	20
306	COVID-19 disease severity in US Veterans infected during Omicron and Delta variant predominant periods. <i>Nature Communications</i> , 2022, 13, .	5.8	29
309	The SARS-CoV-2 Delta variant induces an antibody response largely focused on class 1 and 2 antibody epitopes. <i>PLoS Pathogens</i> , 2022, 18, e1010592.	2.1	13
310	Shifting mutational constraints in the SARS-CoV-2 receptor-binding domain during viral evolution. <i>Science</i> , 2022, 377, 420-424.	6.0	140
311	Detection of SARS-CoV-2 intra-host recombination during superinfection with Alpha and Epsilon variants in New York City. <i>Nature Communications</i> , 2022, 13, .	5.8	22
312	Description of a One-Year Succession of Variants of Interest and Concern of SARS-CoV-2 in Venezuela. <i>Viruses</i> , 2022, 14, 1378.	1.5	6
313	The humoral response and antibodies against SARS-CoV-2 infection. <i>Nature Immunology</i> , 2022, 23, 1008-1020.	7.0	84
314	COVID-19 Variant Detection with a High-Fidelity CRISPR-Cas12 Enzyme. <i>Journal of Clinical Microbiology</i> , 2022, 60, .	1.8	18
315	Epidemiological Characteristics of COVID-19 and Effective Public Health Interventions in Shenzhen, China. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	2
318	The structural role of SARS-CoV-2 genetic background in the emergence and success of spike mutations: The case of the spike A222V mutation. <i>PLoS Pathogens</i> , 2022, 18, e1010631.	2.1	11
319	Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7675.	1.8	9
320	Admissions to a large tertiary care hospital and Omicron BA.1 and BA.2 SARS-CoV-2 polymerase chain reaction positivity: primary, contributing, or incidental COVID-19. <i>International Journal of Infectious Diseases</i> , 2022, 122, 665-668.	1.5	16
321	A panel of nanobodies recognizing conserved hidden clefts of all SARS-CoV-2 spike variants including Omicron. <i>Communications Biology</i> , 2022, 5, .	2.0	26
322	The COVID-19 Vaccination Still Matters: Omicron Variant Is a Final Wake-Up Call for the Rich to Help the Poor. <i>Vaccines</i> , 2022, 10, 1070.	2.1	10
324	SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns. <i>Cell Host and Microbe</i> , 2022, 30, 1231-1241.e6.	5.1	55

#	ARTICLE	IF	CITATIONS
325	Detecting lineage-defining mutations in SARS-CoV-2 using colorimetric RT-LAMP without probes or additional primers. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
327	Exploring the Chinese Public's Perception of Omicron Variants on Social Media: LDA-Based Topic Modeling and Sentiment Analysis. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 8377.	1.2	4
328	Neutralization capacity of antibodies elicited through homologous or heterologous infection or vaccination against SARS-CoV-2 VOCs. <i>Nature Communications</i> , 2022, 13, .	5.8	53
329	SARS-CoV-2 Testing of Aircraft Wastewater Shows That Mandatory Tests and Vaccination Pass before Boarding Did Not Prevent Massive Importation of Omicron Variant into Europe. <i>Viruses</i> , 2022, 14, 1511.	1.5	9
330	Differences between Omicron SARS-CoV-2 RBD and other variants in their ability to interact with cell receptors and monoclonal antibodies. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 5707-5727.	2.0	7
331	SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. <i>Nature Microbiology</i> , 2022, 7, 1161-1179.	5.9	352
332	COVID-19 disease severity in persons infected with the Omicron variant compared with the Delta variant in Qatar. <i>Journal of Global Health</i> , 0, 12, .	1.2	48
333	Pre-Clinical Development of a Potent Neutralizing Antibody MW3321 With Extensive SARS-CoV-2 Variants Coverage. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	0
336	Viral load of SARS-CoV-2 Omicron is not high despite its high infectivity. <i>Journal of Medical Virology</i> , 2022, 94, 5543-5546.	2.5	22
337	Knowledge and Attitudes towards COVID-19 Prevention Measures among Residents of Lusaka District in Zambia. <i>Aquademia</i> , 2022, 6, ep22005.	0.3	7
338	Reduced Pathogenicity and Transmission Potential of Omicron BA.1 and BA.2 Sublineages Compared with the Early Severe Acute Respiratory Syndrome Coronavirus 2 D614G Variant in Syrian Hamsters. <i>Journal of Infectious Diseases</i> , 2023, 227, 1143-1152.	1.9	16
341	Potential Opportunities and Challenges of Deploying Next Generation Sequencing and CRISPR-Cas Systems to Support Diagnostics and Surveillance Towards Malaria Control and Elimination in Africa. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	6
342	Omicron: a shift in the biology of SARS-CoV-2. <i>Nature Microbiology</i> , 2022, 7, 1114-1115.	5.9	5
343	Shared N417-Dependent Epitope on the SARS-CoV-2 Omicron, Beta, and Delta Plus Variants. <i>Journal of Virology</i> , 2022, 96, .	1.5	7
344	SARS-CoV-2 BA.1 and BA.2 coinfection detected by genomic surveillance in Brazil, January 2022. <i>Archives of Virology</i> , 0, , .	0.9	3
346	Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination. <i>International Journal of Infectious Diseases</i> , 2022, 122, 793-801.	1.5	17
347	Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies. <i>EBioMedicine</i> , 2022, 82, 104158.	2.7	128
348	Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study. <i>EClinicalMedicine</i> , 2022, 50, 101529.	3.2	3

#	ARTICLE	IF	CITATIONS
349	Intrinsic generation time of the SARS-CoV-2 Omicron variant: An observational study of household transmission. <i>Lancet Regional Health - Europe</i> , The, 2022, 19, 100446.	3.0	34
350	Increasing contributions of airborne route in SARS-CoV-2 omicron variant transmission compared with the ancestral strain. <i>Building and Environment</i> , 2022, 221, 109328.	3.0	13
351	Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2. <i>Antiviral Research</i> , 2022, 205, 105372.	1.9	22
352	Identification of a novel immune-inflammatory signature of COVID-19 infections, and evaluation of pharmacokinetics and therapeutic potential of RXn-02, a novel small-molecule derivative of quinolone. <i>Computers in Biology and Medicine</i> , 2022, 148, 105814.	3.9	8
353	Patient-derived monoclonal antibody neutralizes SARS-CoV-2 Omicron variants and confers full protection in monkeys. <i>Nature Microbiology</i> , 2022, 7, 1376-1389.	5.9	33
354	Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission. <i>Reviews in Medical Virology</i> , 2022, 32, .	3.9	276
355	Unsuppressed HIV infection impairs T cell responses to SARS-CoV-2 infection and abrogates T cell cross-recognition. <i>ELife</i> , 0, 11, .	2.8	12
356	Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper. <i>Journal of Hepatology</i> , 2022, 77, 1161-1197.	1.8	46
357	An Overview of Neurological and Psychiatric Complications During Post-COVID Period: A Narrative Review. <i>Journal of Inflammation Research</i> , 0, Volume 15, 4199-4215.	1.6	4
358	Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Infection With accumulation of mutations in a patient with poorly controlled Human Immunodeficiency Virus infection. <i>Clinical Infectious Diseases</i> , 2023, 76, e522-e525.	2.9	35
359	Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines. <i>Science</i> , 2022, 377, 890-894.	6.0	142
360	SARS-CoV-2 and Emerging Foodborne Pathogens: Intriguing Commonalities and Obvious Differences. <i>Pathogens</i> , 2022, 11, 837.	1.2	0
361	Neutralization of distinct Omicron sublineages by longitudinal vaccination sera. <i>Journal of Medical Virology</i> , 2022, 94, 5090-5092.	2.5	7
362	SARS-CoV-2's Variants of Concern: A Brief Characterization. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	31
363	Addressing the Needs of People with Schizophrenia in South Africa During the COVID-19 Pandemic. <i>Schizophrenia Bulletin Open</i> , 2022, 3, .	0.9	1
365	Genomic evidence for divergent co-infections of co-circulating SARS-CoV-2 lineages. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 4015-4024.	1.9	14
366	Dynamics of competing SARS-CoV-2 variants during the Omicron epidemic in England. <i>Nature Communications</i> , 2022, 13, .	5.8	22
367	COVID-19 Vaccine Booster Strategies for Omicron SARS-CoV-2 Variant: Effectiveness and Future Prospects. <i>Vaccines</i> , 2022, 10, 1223.	2.1	12

#	ARTICLE	IF	CITATIONS
369	SARS-CoV-2 Is Not Special, but the Pandemic Is: The Ecology, Evolution, Policy, and Future of the Deadliest Pandemic in Living Memory. <i>Annual Review of Anthropology</i> , 2022, 51, 527-548.	0.4	2
370	Omicron Wave Modification of the Coronavirus Disease 2019 Paradigm in Children With Cystic Fibrosis. <i>Journal of Infectious Diseases</i> , 2023, 227, 831-832.	1.9	3
371	Evidence of recurrent selection of mutations commonly found in SARS-CoV-2 variants of concern in viruses infecting immunocompromised patients. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	5
372	SARS-CoV-2 S2â€“targeted vaccination elicits broadly neutralizing antibodies. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	57
375	Characterization of the Antibody and Interferon-Gamma Release Response after a Second COVID-19 Booster Vaccination. <i>Vaccines</i> , 2022, 10, 1163.	2.1	4
376	Sensitivity and Specificity of Patient-Reported Clinical Manifestations to Diagnose COVID-19 in Adults from a National Database in Chile: A Cross-Sectional Study. <i>Biology</i> , 2022, 11, 1136.	1.3	1
377	BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adults. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	16
378	Tracking the turnover of SARS-CoV-2 VOCs Gamma to Delta in a Brazilian state (Minas Gerais) with a high-vaccination status. <i>Virus Evolution</i> , 2022, 8, .	2.2	10
379	A survey of Judaeo-Christian books initially responding to the COVID-19 pandemic. <i>Practical Theology</i> , 0, , 1-21.	0.1	0
382	The origins and molecular evolution of SARS-CoV-2 lineage B.1.1.7 in the UK. <i>Virus Evolution</i> , 2022, 8, .	2.2	75
383	Disease severity and efficacy of homologous vaccination among patients infected with SARSâ€“CoVâ€“2 Delta or Omicron VOCs, compared to unvaccinated using main biomarkers. <i>Journal of Medical Virology</i> , 2022, 94, 5867-5876.	2.5	17
384	COVID-19 pandemic dynamics in South Africa and epidemiological characteristics of three variants of concern (Beta, Delta, and Omicron). <i>ELife</i> , 0, 11, .	2.8	36
386	Change in Seizure Incidence in Febrile Children With COVID-19 in the Era of Omicron Variant of Concern. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2022, 11, 514-517.	0.6	20
387	Subâ€“lineages of the SARSâ€“CoVâ€“2 Omicron variants:â€“Characteristics and prevention. <i>MedComm</i> , 2022, 3, .	3.1	15
388	A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern. <i>MBio</i> , 2022, 13, .	1.8	28
389	Antibody escape and cryptic cross-domain stabilization in the SARS-CoV-2 Omicron spike protein. <i>Cell Host and Microbe</i> , 2022, 30, 1242-1254.e6.	5.1	27
392	Immunity after COVID-19 vaccination in people with higher risk of compromised immune status: a scoping review. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	9
393	Effects of boosted mRNA and adenoviralâ€“vectored vaccines on immune responses to omicron BA.1 and BA.2 following the heterologous CoronaVac/AZD1222 vaccination. <i>Journal of Medical Virology</i> , 2022, 94, 5713-5722.	2.5	23

#	ARTICLE	IF	CITATIONS
394	Epidemiologic characteristics of SARS-CoV-2 in Wuhan, other regions of China, and globally based on data gathered from January 2020 to February 2021. <i>Medicine (United States)</i> , 2022, 101, e30019.	0.4	3
396	Effectiveness of the BNT162b2 mRNA Vaccine Compared with Hybrid Immunity in Populations Prioritized and Non-Prioritized for COVID-19 Vaccination in 2021â€“2022: A Naturalistic Case-Control Study in Sweden. <i>Vaccines</i> , 2022, 10, 1273.	2.1	1
397	BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19. <i>Nature Communications</i> , 2022, 13, .	5.8	29
398	Uninvited Guest: Arrival and Dissemination of Omicron Lineage SARS-CoV-2 in St. Petersburg, Russia. <i>Microorganisms</i> , 2022, 10, 1676.	1.6	5
399	The Impact of Shanghai Epidemic, China, 2022 on Public Psychology: A Sentiment Analysis of Microblog Users by Data Mining. <i>Sustainability</i> , 2022, 14, 9649.	1.6	2
401	Characterization of the expressed RNA variants from young patients with critical and non-critical SARS-CoV-2 infection. <i>Egyptian Journal of Medical Human Genetics</i> , 2022, 23, .	0.5	0
402	Recombinant Decoy Exhibits Broad Protection against Omicron and Resistance Potential to Future Variants. <i>Pharmaceuticals</i> , 2022, 15, 1002.	1.7	3
403	Genomic Surveillance of SARS-CoV-2 in the Southern Province of Zambia: Detection and Characterization of Alpha, Beta, Delta, and Omicron Variants of Concern. <i>Viruses</i> , 2022, 14, 1865.	1.5	1
405	The Omicron Variant BA.1.1 Presents a Lower Pathogenicity than B.1 D614G and Delta Variants in a Feline Model of SARS-CoV-2 Infection. <i>Journal of Virology</i> , 2022, 96, .	1.5	35
406	Clinical characteristics of pediatric patients with COVID-19 between Omicron era vs. pre-Omicron era. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 1501-1505.	0.8	14
409	SARS-CoV-2 Evolution and Patient Immunological History Shape the Breadth and Potency of Antibody-Mediated Immunity. <i>Journal of Infectious Diseases</i> , 2022, 227, 40-49.	1.9	6
410	The Omicron variant of concern: The genomics, diagnostics, and clinical characteristics in children. <i>Frontiers in Pediatrics</i> , 0, 10, .	0.9	19
411	Identification of key molecules in COVID-19 patients significantly correlated with clinical outcomes by analyzing transcriptomic data. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
412	Containing novel SARS-CoV-2 variants at source is possible with high-intensity sequencing. , 2022, 1, .		3
413	Lineage BA.2 Dominated the Omicron SARS-CoV-2 Epidemic Wave in the Philippines. <i>Virus Evolution</i> , 0, , .	2.2	2
414	Unravelling the Mechanistic Role of ACE2 and TMPRSS2 in Hypertension: A Risk Factor for COVID-19. <i>Current Hypertension Reviews</i> , 2022, 18, 130-137.	0.5	5
416	Decoding the Role of Temperature in RNA Virus Infections. <i>MBio</i> , 2022, 13, .	1.8	10
417	A mixed methods study evaluating acceptability of a daily COVID-19 testing regimen with a mobile-app connected, at-home, rapid antigen test: Implications for current and future pandemics. <i>PLoS ONE</i> , 2022, 17, e0267766.	1.1	8

#	ARTICLE	IF	CITATIONS
418	Delineating the Spread and Prevalence of SARS-CoV-2 Omicron Sublineages (BA.1 and BA.5) and Deltacron Using Wastewater in the Western Cape, South Africa. <i>Journal of Infectious Diseases</i> , 2022, 226, 1418-1427.	1.9	10
420	Genomic epidemiology of the SARS-CoV-2 epidemic in Brazil. <i>Nature Microbiology</i> , 2022, 7, 1490-1500.	5.9	49
422	Promotion of neutralizing antibody-independent immunity to wild-type and SARS-CoV-2 variants of concern using an RBD-Nucleocapsid fusion protein. <i>Nature Communications</i> , 2022, 13, .	5.8	12
423	Ultrarapid and ultrasensitive detection of SARS-CoV-2 antibodies in COVID-19 patients via a 3D-printed nanomaterial-based biosensing platform. <i>Journal of Medical Virology</i> , 2022, 94, 5808-5826.	2.5	8
424	Protective antibodies and T cell responses to Omicron variant after the booster dose of BNT162b2 vaccine. <i>Cell Reports Medicine</i> , 2022, 3, 100716.	3.3	16
425	Validation of the COVID-19 IgG/IgM Rapid Test Cassette (BNCP 402 and BNCP402) in a South African setting. <i>Southern African Journal of Infectious Diseases</i> , 2022, 37, .	0.3	0
426	Neutralizing antibodies to SARS-CoV-2 variants of concern including Delta and Omicron in subjects receiving mRNA-1273, BNT162b2, and Ad26.COV2.S vaccines. <i>Journal of Medical Virology</i> , 2022, 94, 5678-5690.	2.5	16
427	Biochemical Characterization of Emerging SARS-CoV-2 Nsp15 Endoribonuclease Variants. <i>Journal of Molecular Biology</i> , 2022, 434, 167796.	2.0	4
428	Clinical Evaluation of Severe Acute Respiratory Syndrome Coronavirus 2 Rapid Antigen Tests During the Omicron Wave in South Africa. <i>Journal of Infectious Diseases</i> , 2022, 226, 1412-1417.	1.9	8
431	Antibody response against SARS-CoV-2 variants of concern in children infected with pre-Omicron variants: An observational cohort study. <i>EBioMedicine</i> , 2022, 83, 104230.	2.7	11
432	Replicating RNA platform enables rapid response to the SARS-CoV-2 Omicron variant and elicits enhanced protection in naïve hamsters compared to ancestral vaccine. <i>EBioMedicine</i> , 2022, 83, 104196.	2.7	26
433	Neutralizing immunity against SARS-CoV-2 Omicron BA.1 by infection and vaccination. <i>IScience</i> , 2022, 25, 104886.	1.9	5
434	Parental hesitancy towards vaccinating their children with a booster dose against COVID-19: Real-world evidence from Taizhou, China. <i>Journal of Infection and Public Health</i> , 2022, 15, 1006-1012.	1.9	7
435	Replication of SARS-CoV-2 Omicron BA.2 variant in ex vivo cultures of the human upper and lower respiratory tract. <i>EBioMedicine</i> , 2022, 83, 104232.	2.7	48
436	Omicron variant (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2?. <i>Biomedicine and Pharmacotherapy</i> , 2022, 154, 113522.	2.5	56
437	Omicron BA.1 and BA.2 variants increase the interactions of SARS-CoV-2 spike glycoprotein with ACE2. <i>Journal of Molecular Graphics and Modelling</i> , 2022, 117, 108286.	1.3	20
438	Sewage surveillance of SARS-CoV-2 at student campus residences in the Western Cape, South Africa. <i>Science of the Total Environment</i> , 2022, 851, 158028.	3.9	9
439	Research progress of biosensors for detection of SARS-CoV-2 variants based on ACE2. <i>Talanta</i> , 2023, 251, 123813.	2.9	12

#	ARTICLE	IF	CITATIONS
440	A prospective study of risk factors associated with seroprevalence of SARS-CoV-2 antibodies in healthcare workers at a large UK teaching hospital. <i>Journal of Infection</i> , 2022, 85, 557-564.	1.7	7
441	Structural basis of a two-antibody cocktail exhibiting highly potent and broadly neutralizing activities against SARS-CoV-2 variants including diverse Omicron sublineages. <i>Cell Discovery</i> , 2022, 8, .	3.1	13
442	SARS-CoV-2 infection in pediatric population before and during the Delta (B.1.617.2) and Omicron (B.1.1.529) variants era. <i>Virology Journal</i> , 2022, 19, .	1.4	41
443	Genomic surveillance of SARS-CoV-2 Omicron variants on a university campus. <i>Nature Communications</i> , 2022, 13, .	5.8	15
444	Regional importation and asymmetric within-country spread of SARS-CoV-2 variants of concern in the Netherlands. <i>ELife</i> , 0, 11, .	2.8	12
445	The mechanisms of immune response and evasion by the main SARS-CoV-2 variants. <i>IScience</i> , 2022, 25, 105044.	1.9	8
446	Plaque-neutralizing antibody to BA.2.12.1, BA.4 and BA.5 in individuals with three doses of BioNTech or CoronaVac vaccines, natural infection and breakthrough infection. <i>Journal of Clinical Virology</i> , 2022, 156, 105273.	1.6	19
447	Antibody and T-cellular response to COVID-19 booster vaccine in SARS-CoV-1 survivors. <i>Clinical Immunology</i> , 2022, 244, 109103.	1.4	3
448	Epidemiological characteristics and transmission dynamics of the outbreak caused by the SARS-CoV-2 Omicron variant in Shanghai, China: A descriptive study. <i>The Lancet Regional Health - Western Pacific</i> , 2022, 29, 100592.	1.3	62
449	Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial. <i>The Lancet Regional Health - Western Pacific</i> , 2022, 29, 100586.	1.3	6
450	BBIBP-CorV Vaccination Reduces COVID-19 Severity Rate and Accelerates Anti-Viral Antibody Responses in Heterologous Omicron Infection. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
451	Plaque-Neutralizing Antibody to BA.2.12.1, BA.4 and BA.5 in Individuals with Three Doses of Biontech or Coronavac Vaccines, Natural Infection and Breakthrough Infection. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
452	Leveraging International Influenza Surveillance Systems and Programs during the COVID-19 Pandemic. <i>Emerging Infectious Diseases</i> , 2022, 28, .	2.0	8
453	O impacto da disponibilidade de dados e informaÃ§Ã£o oportuna para a vigilÃ¢ncia epidemiolÃ³gica. <i>Cadernos De Saude Publica</i> , 2022, 38, .	0.4	0
454	Durability of ChAdOx1 nCoV-19 (AZD1222) Vaccine and Hybrid Humoral Immunity Against Variants Including Omicron BA.1 and BA.4 Six Months after Vaccination: A Randomised, Phase 1b/2a Trial. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
455	Characteristics of the SARS-CoV-2 Omicron (B.1.1.529) Variant and Emerging Impact on Global Public Health. <i>BMC Clinical Pathology</i> , 2022, 15, 2632010X2211249.	0.7	14
456	SARS-CoV-2 Vaccine Against Virus: Mission Accomplished!?. , 2022, , 561-574.		0
457	Titers and Capacity of Neutralizing Antibodies Against SARS-CoV-2 Variants after Heterologous Booster Vaccination in Health Care Workers Primed with Two Doses of ChadOx1 nCov-19: A Single-Blinded, Randomized Clinical Trial. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
458	Importance of data availability and timely information for epidemiological surveillance. <i>Cadernos De Saude Publica</i> , 2022, 38, .	0.4	1
459	El impacto de la disponibilidad de datos e informaci3n oportuna para la vigilancia epidemiol3gica. <i>Cadernos De Saude Publica</i> , 2022, 38, .	0.4	0
460	Antibody-mediated immunity to SARS-CoV-2 spike. <i>Advances in Immunology</i> , 2022, , 1-69.	1.1	12
461	COVID-19 Infection: The Virus and Its Origin, the Variants, the Immune Defense, the Multiorgan Autoimmune Reactions, and the Targeted Treatments. <i>Advances in Infectious Diseases</i> , 2022, 12, 568-631.	0.0	1
462	The Double-slit experiment and Feynman Amplitudes to Interpret the Rise of Omicron at the Covid-19 Pandemic at 2022. , 2022, , .		0
463	Early Detection of SARS-CoV-2 Omicron BA.4 and BA.5 in German Wastewater. <i>Viruses</i> , 2022, 14, 1876.	1.5	12
464	Clinical practice of rapid antigen tests for SARS-CoV-2 Omicron variant: A single-center study in China. <i>Virologica Sinica</i> , 2022, 37, 842-849.	1.2	5
466	SARS-CoV-2 Genetic Diversity and Lineage Dynamics in Egypt during the First 18 Months of the Pandemic. <i>Viruses</i> , 2022, 14, 1878.	1.5	4
467	A potent neutralizing antibody provides protection against SARS-CoV-2 Omicron and Delta variants via nasal delivery. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	10
470	Predicting SARS-CoV-2 Variant Spread in a Completely Seropositive Population Using Semi-Quantitative Antibody Measurements in Blood Donors. <i>Vaccines</i> , 2022, 10, 1437.	2.1	5
472	Low SARS-CoV-2 viral load among vaccinated individuals infected with Delta B.1.617.2 and Omicron BA.1.1.529 but not with Omicron BA.1.1 and BA.2 variants. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	7
475	Antibody Response against Circulating Omicron Variants 8 Months after the Third Dose of mRNA Vaccine. <i>Vaccines</i> , 2022, 10, 1512.	2.1	3
477	Relative Hypercoagulopathy of the SARS-CoV-2 Beta and Delta Variants when Compared to the Less Severe Omicron Variants Is Related to TEG Parameters, the Extent of Fibrin Amyloid Microclots, and the Severity of Clinical Illness. <i>Seminars in Thrombosis and Hemostasis</i> , 2022, 48, 858-868.	1.5	26
478	Covid-19 Vaccines â€” Immunity, Variants, Boosters. <i>New England Journal of Medicine</i> , 2022, 387, 1011-1020.	13.9	266
479	COVID-19 in Older Adults at the Time of the Omicron Variant. <i>Journal of Clinical Medicine</i> , 2022, 11, 5273.	1.0	3
480	Screening and Characterization of Shark-Derived VNARs against SARS-CoV-2 Spike RBD Protein. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10904.	1.8	8
481	The SARS-CoV-2 Omicron BA.1 spike G446S mutation potentiates antiviral T-cell recognition. <i>Nature Communications</i> , 2022, 13, .	5.8	15
484	COVIDâ€™19 vaccinations and rates of infections, hospitalizations, ICU admissions, and deaths in Europe during SARSâ€™CoVâ€™2 Omicron wave in the first quarter of 2022. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	10

#	ARTICLE	IF	CITATIONS
485	Electrostatic Features for the Receptor Binding Domain of SARS-COV-2 Wildtype and Its Variants. Compass to the Severity of the Future Variants with the Charge-Rule. <i>Journal of Physical Chemistry B</i> , 2022, 126, 6835-6852.	1.2	19
488	SARS-CoV-2 Variant Surveillance in Genomic Medicine Era. <i>Infectious Diseases</i> , 0, , .	4.0	0
489	The Spike-Stabilizing D614G Mutation Interacts with S1/S2 Cleavage Site Mutations To Promote the Infectious Potential of SARS-CoV-2 Variants. <i>Journal of Virology</i> , 2022, 96, .	1.5	6
490	Differences in Clinical Presentations of Omicron Infections with the Lineages BA.2 and BA.5 in Mecklenburg-Western Pomerania, Germany, between April and July 2022. <i>Viruses</i> , 2022, 14, 2033.	1.5	8
493	Immunogenicity and safety of third-dose mRNA COVID-19 vaccines in healthy adults previously vaccinated with two doses of the ChAdOx1 vaccine. <i>Journal of the Formosan Medical Association</i> , 2023, 122, 121-131.	0.8	9
494	Cheminformatics-Based Discovery of Potential Chemical Probe Inhibitors of Omicron Spike Protein. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10315.	1.8	7
496	SARS-CoV-2 Variants Identification: Overview of Molecular Existing Methods. <i>Pathogens</i> , 2022, 11, 1058.	1.2	20
497	Reevaluation of antibody-dependent enhancement of infection in anti-SARS-CoV-2 therapeutic antibodies and mRNA-vaccine antisera using FcR- and ACE2-positive cells. <i>Scientific Reports</i> , 2022, 12, .	1.6	19
498	Enhanced antibody responses in fully vaccinated individuals against pan-SARS-CoV-2 variants following Omicron breakthrough infection. <i>Cell Reports Medicine</i> , 2022, 3, 100764.	3.3	16
499	Investigating the evolutionary origins of the first three SARS-CoV-2 variants of concern. <i>Frontiers in Virology</i> , 0, 2, .	0.7	14
501	Virological features and pathogenicity of SARS-CoV-2 Omicron BA.2. <i>Cell Reports Medicine</i> , 2022, 3, 100743.	3.3	19
502	Microbiological and Clinical Findings of SARS-CoV-2 Infection after 2 Years of Pandemic: From Lung to Gut Microbiota. <i>Diagnostics</i> , 2022, 12, 2143.	1.3	4
504	Population genetic models for the spatial spread of adaptive variants: A review in light of SARS-CoV-2 evolution. <i>PLoS Genetics</i> , 2022, 18, e1010391.	1.5	5
505	Serial infection with SARS-CoV-2 Omicron BA.1 and BA.2 following three-dose COVID-19 vaccination. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
506	National response to the COVID-19 Omicron variant crisis in the ambulatory hemodialysis service in the State of Qatar. <i>Qatar Medical Journal</i> , 2022, 2022, .	0.2	5
507	An Update on Complications Associated with SARS-CoV-2 Infection and COVID-19 Vaccination. <i>Vaccines</i> , 2022, 10, 1639.	2.1	1
508	Spike mutations contributing to the altered entry preference of SARS-CoV-2 omicron BA.1 and BA.2. <i>Emerging Microbes and Infections</i> , 2022, 11, 2275-2287.	3.0	48
509	Clinical characteristics of liver injury in SARS-CoV-2 Omicron variant- and Omicron subvariant-infected patients. <i>Annals of Hepatology</i> , 2023, 28, 100763.	0.6	4

#	ARTICLE	IF	CITATIONS
510	Vaccine Effectiveness against SARS-CoV-2 Variants in Adolescents from 15 to 90 Days after Second Dose: A Population-Based Test-Negative Case-Control Study. <i>Journal of Pediatrics</i> , 2023, 253, 189-196.e2.	0.9	5
512	An ACE2 decoy can be administered by inhalation and potently targets omicron variants of SARS-CoV-2. <i>EMBO Molecular Medicine</i> , 2022, 14, .	3.3	28
513	SARS-CoV-2 reinfections during the Delta and Omicron waves. <i>JCI Insight</i> , 2022, 7, .	2.3	5
515	Intrahost SARS-CoV-2 k-mer Identification Method (iSKIM) for Rapid Detection of Mutations of Concern Reveals Emergence of Global Mutation Patterns. <i>Viruses</i> , 2022, 14, 2128.	1.5	0
516	Epistatic Variations in the Omicron Receptor Binding Domain Can Enhance Host Recognition: An In Silico Assessment and Prediction. <i>Journal of Physical Chemistry Letters</i> , 2022, 13, 8808-8815.	2.1	2
518	SARS-CoV-2 variants from COVID-19 positive cases in the Free State province, South Africa from July 2020 to December 2021. <i>Frontiers in Virology</i> , 0, 2, .	0.7	2
520	Role for N-glycans and calnexin-calreticulin chaperones in SARS-CoV-2 Spike maturation and viral infectivity. <i>Science Advances</i> , 2022, 8, .	4.7	10
521	Information technology and artificial intelligence support in management experiences of the pediatric designated hospital during the COVID-19 epidemic in 2022 in Shanghai. <i>Intelligent Medicine</i> , 2023, 3, 16-21.	1.6	5
522	Scaling Biosafety Up During and Down After the COVID-19 Pandemic. <i>Applied Biosafety</i> , 2022, 27, 247-254.	0.2	1
524	Impact of antigen test target failure and testing strategies on the transmission of SARS-CoV-2 variants. <i>Nature Communications</i> , 2022, 13, .	5.8	12
525	Coronavirus Host Genomics Study: South Africa (COVIGen-SA). <i>Global Health, Epidemiology and Genomics</i> , 2022, 2022, 1-14.	0.2	0
526	Druggable targets and therapeutic development for COVID-19. <i>Frontiers in Chemistry</i> , 0, 10, .	1.8	4
528	Methods for early characterisation of the severity and dynamics of SARS-CoV-2 variants: a population-based time series analysis in South Africa. <i>Lancet Microbe</i> , The, 2022, 3, e753-e761.	3.4	7
529	Effectiveness and durability of BNT162b2 vaccine against hospital and emergency department admissions due to SARS-CoV-2 omicron sub-lineages BA.1 and BA.2 in a large health system in the USA: a test-negative, case-control study. <i>Lancet Respiratory Medicine</i> , the, 2023, 11, 176-187.	5.2	17
531	The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly expanding genomic surveillance. <i>Science</i> , 2022, 378, .	6.0	64
532	Duration of BA.5 neutralization in sera and nasal swabs from SARS-CoV-2 vaccinated individuals, with or without omicron breakthrough infection. <i>Med</i> , 2022, 3, 838-847.e3.	2.2	26
534	SARS-CoV-2 variants impact RBD conformational dynamics and ACE2 accessibility. <i>Frontiers in Medical Technology</i> , 0, 4, .	1.3	6
535	An international observational study to assess the impact of the Omicron variant emergence on the clinical epidemiology of COVID-19 in hospitalised patients. <i>ELife</i> , 0, 11, .	2.8	8

#	ARTICLE	IF	CITATIONS
536	Older age and depressive state are risk factors for re-positivity with SARS-CoV-2 Omicron variant. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	3
537	Vaccine models predict rules for updating vaccines against evolving pathogens such as SARS-CoV-2 and influenza in the context of pre-existing immunity. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
538	A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two doses. <i>Cell Reports</i> , 2022, 41, 111554.	2.9	14
539	Ad5-nCoV booster and Omicron variant breakthrough infection following two doses of inactivated vaccine elicit comparable antibody levels against Omicron variants. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	10
540	COVID-19 and Alzheimer's Disease: Neuroinflammation, Oxidative Stress, Ferroptosis, and Mechanisms Involved. <i>Current Medicinal Chemistry</i> , 2023, 30, 3993-4031.	1.2	6
541	Characteristics of post-Wuhan COVID-19 outbreaks in mainland China. , 2022, 2, 7.		1
542	Fast, low-cost and highly specific colorimetric RT-LAMP assays for inference of SARS-CoV-2 Omicron BA.1 and BA.2 lineages. <i>Analyst</i> , The, 2022, 147, 5613-5622.	1.7	1
543	Global estimates of the fitness advantage of SARS-CoV-2 variant Omicron. <i>Virus Evolution</i> , 2022, 8, .	2.2	4
544	Temperature Influences the Interaction between SARS-CoV-2 Spike from Omicron Subvariants and Human ACE2. <i>Viruses</i> , 2022, 14, 2178.	1.5	5
546	Validation of a new strategy for the identification of SARS-CoV-2 variants by sequencing the spike gene by Sanger. <i>Enfermedades Infecciosas Y Microbiologia Clinica (English Ed)</i> , 2023, 41, 284-289.	0.2	1
547	Detection and prevalence of SARS-CoV-2 co-infections during the Omicron variant circulation in France. <i>Nature Communications</i> , 2022, 13, .	5.8	33
549	Effectiveness of vaccination against SARS-CoV-2 Omicron variant infection, symptomatic disease, and hospitalization: a systematic review and meta-analysis. <i>Expert Review of Vaccines</i> , 2022, 21, 1831-1841.	2.0	10
550	SARS-CoV-2 Omicron variant is attenuated for replication in a polarized human lung epithelial cell model. <i>Communications Biology</i> , 2022, 5, .	2.0	34
551	Clinical phenotypes and outcomes associated with SARS-CoV-2 variant Omicron in critically ill French patients with COVID-19. <i>Nature Communications</i> , 2022, 13, .	5.8	33
552	COVID-19 vaccine booster significantly decreases the risk of intensive care unit hospitalization in heart failure patients during the Omicron variant wave: A population-based study. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	3
553	Effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines against SARS-CoV-2 Omicron BA. 2 variant infection, severe illness, and death. <i>BMC Medicine</i> , 2022, 20, .	2.3	51
554	Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-c-2a trial. <i>Lancet Infectious Diseases</i> , The, 2023, 23, 295-306.	4.6	14
555	Infection, pathology and interferon treatment of the SARS-CoV-2 Omicron BA.1 variant in juvenile, adult and aged Syrian hamsters. , 2022, 19, 1392-1399.		5

#	ARTICLE	IF	CITATIONS
556	Extensive neutralization against SARS-CoV-2 variants elicited by Omicron-specific subunit vaccine as a heterologous booster. <i>IScience</i> , 2022, 25, 105465.	1.9	2
557	Molecular and Structural Analysis of Specific Mutations from Saudi Isolates of SARS-CoV-2 RNA-Dependent RNA Polymerase and their Implications on Protein Structure and Drug-Protein Binding. <i>Molecules</i> , 2022, 27, 6475.	1.7	8
558	Dual-targeting cyclic peptides of receptor-binding domain (RBD) and main protease (Mpro) as potential drug leads for the treatment of SARS-CoV-2 infection. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
560	SARS-COV-2 antibody responses to AZD1222 vaccination in West Africa. <i>Nature Communications</i> , 2022, 13, .	5.8	14
561	Vaccine effectiveness of primary series and booster doses against covid-19 associated hospital admissions in the United States: living test negative design study. <i>BMJ</i> , The, 0, , e072065.	3.0	54
562	Supply of basic necessities to vulnerable populations during the COVID-19 pandemic: Empirical evidence from Shanghai, China. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	3
563	Quantum Chemical Computation of Omicron Mutations Near Cleavage Sites of the Spike Protein. <i>Microorganisms</i> , 2022, 10, 1999.	1.6	4
564	Strategies for Using Antigen Rapid Diagnostic Tests to Reduce Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 in Low- and Middle-Income Countries: A Mathematical Modelling Study Applied to Zambia. <i>Clinical Infectious Diseases</i> , 2023, 76, 620-630.	2.9	10
565	Microalgae as an Efficient Vehicle for the Production and Targeted Delivery of Therapeutic Glycoproteins against SARS-CoV-2 Variants. <i>Marine Drugs</i> , 2022, 20, 657.	2.2	11
566	HaploDMF: viral haplotype reconstruction from long reads via deep matrix factorization. <i>Bioinformatics</i> , 2022, 38, 5360-5367.	1.8	1
567	Two Years of Genomic Surveillance in Belgium during the SARS-CoV-2 Pandemic to Attain Country-Wide Coverage and Monitor the Introduction and Spread of Emerging Variants. <i>Viruses</i> , 2022, 14, 2301.	1.5	6
569	Viral dynamics of the SARS-CoV-2 Omicron Variant among household contacts with 2 or 3 COVID-19 vaccine doses. <i>Journal of Infection</i> , 2022, 85, 666-670.	1.7	8
570	Breadth of SARS-CoV-2 neutralization and protection induced by a nanoparticle vaccine. <i>Nature Communications</i> , 2022, 13, .	5.8	31
572	Infection with the SARS-CoV-2 Omicron variant in children with congenital heart disease: A case series study during Shanghai epidemic. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	0
573	Imprinted antibody responses against SARS-CoV-2 Omicron sublineages. <i>Science</i> , 2022, 378, 619-627.	6.0	117
574	Cov2clusters: genomic clustering of SARS-CoV-2 sequences. <i>BMC Genomics</i> , 2022, 23, .	1.2	2
575	SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies. <i>Nature Reviews Microbiology</i> , 2023, 21, 112-124.	13.6	128
576	Evidence for SARS-CoV-2 Delta and Omicron co-infections and recombination. <i>Med</i> , 2022, 3, 848-859.e4.	2.2	25

#	ARTICLE	IF	CITATIONS
577	The latest Omicron BA.4 and BA.5 lineages are frowning toward COVID-19 preventive measures: A threat to global public health. <i>Health Science Reports</i> , 2022, 5, .	0.6	24
579	Rapid Identification of SARS-CoV-2 Omicron BA.5 Spike Mutation F486V in Clinical Specimens Using a High-Resolution Melting-Based Assay. <i>Viruses</i> , 2022, 14, 2401.	1.5	2
581	Effectiveness and safety of Tai Chi for anxiety disorder of COVID-19: A protocol of systematic review and meta-analysis. <i>Medicine (United States)</i> , 2022, 101, e30992.	0.4	2
583	Targeting Natural Plant Metabolites for Hunting SARS-CoV-2 Omicron BA.1 Variant Inhibitors: Extraction, Molecular Docking, Molecular Dynamics, and Physicochemical Properties Study. <i>Current Issues in Molecular Biology</i> , 2022, 44, 5028-5047.	1.0	0
584	Recurrence of Symptoms Following a 2-Day Symptom Free Period in Patients With COVID-19. <i>JAMA Network Open</i> , 2022, 5, e2238867.	2.8	12
585	Vaccine breakthrough infection leads to distinct profiles of neutralizing antibody responses by SARS-CoV-2 variant. <i>JCI Insight</i> , 2022, 7, .	2.3	14
586	Fully understanding the efficacy profile of the COVID-19 vaccination and its associated factors in multiple real-world settings. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
587	SARS-CoV-2 Omicron BA.1, BA.2, and XAC identification during routine surveillance on a university campus in Belo Horizonte, Brazil, 2022. <i>Brazilian Journal of Microbiology</i> , 2022, 53, 2009-2014.	0.8	6
589	Clinical characteristics of pediatric cases infected with the SARS-CoV-2 Omicron variant in a tertiary children's medical center in Shanghai, China. <i>World Journal of Pediatrics</i> , 2023, 19, 87-95.	0.8	7
590	SARS-CoV-2 evolves to reduce but not abolish neutralizing action. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	6
591	RASCL: Rapid Assessment of Selection in CLades through molecular sequence analysis. <i>PLoS ONE</i> , 2022, 17, e0275623.	1.1	2
592	Retrospective analysis of SARS-CoV-2 omicron invasion over delta in French regions in 2021-22: a status-based multi-variant model. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	2
593	Omicron B.1.1.529 subvariant: Brief evidence and future prospects. <i>Annals of Medicine and Surgery</i> , 2022, 83, .	0.5	11
594	Diagnosis of SARS-CoV-2 infection from breath - a proof-of-concept study. <i>IJID Regions</i> , 2022, , .	0.5	0
595	Limited cross-variant immune response from SARS-CoV-2 Omicron BA.2 in naïve but not previously infected outpatients. <i>IScience</i> , 2022, 25, 105369.	1.9	7
596	Identification and differential usage of a host metalloproteinase entry pathway by SARS-CoV-2 Delta and Omicron. <i>IScience</i> , 2022, 25, 105316.	1.9	16
597	Risk Factors for Severe Coronavirus Disease 2019 Among Human Immunodeficiency Virus-Infected and -Uninfected Individuals in South Africa, April 2020-March 2022: Data From Sentinel Surveillance. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	3
598	Safety and immunogenicity following a homologous booster dose of CoronaVac in children and adolescents. <i>Nature Communications</i> , 2022, 13, .	5.8	3

#	ARTICLE	IF	CITATIONS
599	The Impact and Progression of the COVID-19 Pandemic in Bulgaria in Its First Two Years. <i>Vaccines</i> , 2022, 10, 1901.	2.1	5
601	Shifts in global mobility dictate the synchrony of SARS-CoV-2 epidemic waves. <i>Journal of Travel Medicine</i> , 2022, 29, .	1.4	5
602	Compensatory epistasis maintains ACE2 affinity in SARS-CoV-2 Omicron BA.1. <i>Nature Communications</i> , 2022, 13, .	5.8	62
603	Global disparities in SARS-CoV-2 genomic surveillance. <i>Nature Communications</i> , 2022, 13, .	5.8	90
604	Whole-genome sequence analysis reveals the circulation of multiple SARS-CoV-2 variants of concern in Nairobi and neighboring counties, Kenya between March and July 2021. <i>Virology Journal</i> , 2022, 19, .	1.4	1
605	The SARS-CoV-2 Delta-Omicron Recombinant Lineage (XD) Exhibits Immune-Escape Properties Similar to the Omicron (BA.1) Variant. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14057.	1.8	4
606	A scenario modelling analysis to anticipate the impact of COVID-19 vaccination in adolescents and children on disease outcomes in the Netherlands, summer 2021. <i>Eurosurveillance</i> , 2022, 27, .	3.9	5
607	Emergence of SARS-CoV-2 Omicron Variant and strategies for tackling the infection. <i>Immunity, Inflammation and Disease</i> , 2022, 10, .	1.3	9
608	The effects of vaccination on the disease severity and factors for viral clearance and hospitalization in Omicron-infected patients: A retrospective observational cohort study from recent regional outbreaks in China. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	8
609	Impacts of Omicron associated restrictions on vertical distributions of air pollution at a suburb site in Shanghai. <i>Atmospheric Environment</i> , 2023, 294, 119461.	1.9	3
610	Updated vaccine protects against SARS-CoV-2 variants including Omicron (B.1.1.529) and prevents transmission in hamsters. <i>Nature Communications</i> , 2022, 13, .	5.8	11
611	Clinical characteristics and short-term recovery of hyposmia in hospitalized non-severe COVID-19 patients with Omicron variant in Shanghai, China. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	6
613	Omicron Subvariants: Clinical, Laboratory, and Cell Culture Characterization. <i>Clinical Infectious Diseases</i> , 2023, 76, 1276-1284.	2.9	8
614	Correlation of Binding and Neutralizing Antibodies against SARS-CoV-2 Omicron Variant in Infection-Naïve and Convalescent BNT162b2 Recipients. <i>Vaccines</i> , 2022, 10, 1904.	2.1	6
615	An Early and Preliminary Assessment of the Clinical Severity of the Emerging SARS-CoV-2 Omicron Variants in Maharashtra, India. <i>Cureus</i> , 2022, , .	0.2	4
616	Serological responses triggered by different SARS-CoV-2 vaccines against SARS-CoV-2 variants in Taiwan. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
617	Genome characterization, phylogenomic assessment and spatio-temporal dynamics study of highly mutated BA variants from India. <i>Indian Journal of Medical Microbiology</i> , 2022, , .	0.3	1
618	Overview of Antiviral Drug Therapy for COVID-19: Where Do We Stand?. <i>Biomedicines</i> , 2022, 10, 2815.	1.4	3

#	ARTICLE	IF	CITATIONS
619	Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in patients receiving monoclonal antibodies. <i>Cell Reports Medicine</i> , 2022, 3, 100850.	3.3	32
620	SARS-CoV-2 Genomic Diversity in Households Highlights the Challenges of Sequence-Based Transmission Inference. <i>MSphere</i> , 2022, 7, .	1.3	5
622	Structural insights into broadly neutralizing antibodies elicited by hybrid immunity against SARS-CoV-2. <i>Emerging Microbes and Infections</i> , 2023, 12, .	3.0	3
623	Antigenic evolution of SARS-CoV-2 in immunocompromised hosts. <i>Evolution, Medicine and Public Health</i> , 2023, 11, 90-100.	1.1	6
624	Structures of ACE2â€™SIT1 recognized by Omicron variants of SARS-CoV-2. <i>Cell Discovery</i> , 2022, 8, .	3.1	11
625	Impact of cross-border-associated cases on the SARS-CoV-2 epidemic in Switzerland during summer 2020 and 2021. <i>Epidemics</i> , 2022, , 100654.	1.5	3
626	The spike gene target failure (SGTF) genomic signature is highly accurate for the identification of Alpha and Omicron SARS-CoV-2 variants. <i>Scientific Reports</i> , 2022, 12, .	1.6	23
627	Comparison of the duration of viral RNA shedding and anti-SARS-CoV-2 spike IgG and IgM antibody titers in COVID-19 patients who were vaccinated with inactivated vaccines or not: a retrospective study. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	0
628	SARS-CoV-2 variants of concerns in animals: An unmonitored rising health threat. <i>VirusDisease</i> , 2022, 33, 466-476.	1.0	7
629	Titers and breadth of neutralizing antibodies against SARS-CoV-2 variants after heterologous booster vaccination in health care workers primed with two doses of ChAdOx1 nCov-19: A single-blinded, randomized clinical trial. <i>Journal of Clinical Virology</i> , 2022, 157, 105328.	1.6	10
630	Emergence of the Omicron SARS-CoV-2 subvariants during the COVID-19 pandemic. <i>International Journal of Surgery</i> , 2022, 108, 106994.	1.1	3
631	Host Protective Immunity against Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) and the COVID-19 Vaccine-Induced Immunity against SARS-CoV-2 and Its Variants. <i>Viruses</i> , 2022, 14, 2541.	1.5	6
632	Deep mutational scans for ACE2 binding, RBD expression, and antibody escape in the SARS-CoV-2 Omicron BA.1 and BA.2 receptor-binding domains. <i>PLoS Pathogens</i> , 2022, 18, e1010951.	2.1	95
633	Mutational escape prevention by combination of four neutralizing antibodies that target RBD conserved regions and stem helix. <i>Virologica Sinica</i> , 2022, 37, 860-873.	1.2	1
635	Molecular dynamics study on the strengthening behavior of Delta and Omicron SARS-CoV-2 spike RBD improved receptor-binding affinity. <i>PLoS ONE</i> , 2022, 17, e0277745.	1.1	4
636	Analytical performance of the rapid qualitative antigen kit for the detection of SARS-CoV-2 during widespread circulation of the Omicron variant. <i>Journal of Infection and Chemotherapy</i> , 2023, 29, 257-262.	0.8	4
637	Global emerging Omicron variant of SARS-CoV-2: Impacts, challenges and strategies. <i>Journal of Infection and Public Health</i> , 2023, 16, 4-14.	1.9	105
638	Maturation of SARS-CoV-2 Spike-specific memory B cells drives resilience to viral escape. <i>IScience</i> , 2023, 26, 105726.	1.9	9

#	ARTICLE	IF	CITATIONS
639	Impact of SARS-CoV-2 vaccination of children ages 5â€“11 years on COVID-19 disease burden and resilience to new variants in the United States, November 2021â€“March 2022: a multi-model study. <i>The Lancet Regional Health Americas</i> , 2023, 17, 100398.	1.5	7
640	Rapid emergence of omicron sublineages expressing spike protein R346T. <i>Lancet Regional Health - Europe</i> , The, 2023, 24, 100564.	3.0	11
641	Safety and immunogenicity of a third dose of COVID-19 protein subunit vaccine (Covovax TM) after homologous and heterologous two-dose regimens. <i>International Journal of Infectious Diseases</i> , 2023, 126, 64-72.	1.5	12
642	Outcomes of laboratory-confirmed SARS-CoV-2 infection during resurgence driven by Omicron lineages BA.4 and BA.5 compared with previous waves in the Western Cape Province, South Africa. <i>International Journal of Infectious Diseases</i> , 2023, 127, 63-68.	1.5	32
643	Interference reduction isothermal nucleic acid amplification strategy for COVID-19 variant detection. <i>Sensors and Actuators B: Chemical</i> , 2023, 377, 133006.	4.0	2
644	Comorbidities prolonged viral shedding of patients infected with SARS-CoV-2 omicron variant in Shanghai: A multi-center, retrospective, observational study. <i>Journal of Infection and Public Health</i> , 2023, 16, 182-189.	1.9	9
645	A tale of two waves: characteristics and outcomes of COVID-19 admissions during the Omicron-driven fourth wave in Cape Town, South Africa, and implications for the future. <i>IJID Regions</i> , 2023, 6, 42-47.	0.5	3
647	Electrostatic Interactions Are the Primary Determinant of the Binding Affinity of SARS-CoV-2 Spike RBD to ACE2: A Computational Case Study of Omicron Variants. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14796.	1.8	14
649	Characteristics of the severe acute respiratory syndrome coronavirus 2 omicron BA.2 subvariant in Jilin, China from March to May 2022. <i>Journal of Translational Internal Medicine</i> , 2023, 10, 349-358.	1.0	3
651	SARS-CoV-2 Vaccine Strain Selection: Guidance From Influenza. <i>Journal of Infectious Diseases</i> , 0, , .	1.9	0
652	Genome Sequence of a Recombinant SARS-CoV-2 Lineage XAM (BA.1.1/BA.2.9) Strain from a Clinical Sample in Santo Domingo, Dominican Republic. <i>Microbiology Resource Announcements</i> , 0, , .	0.3	0
654	Using nanomaterials to address SARS-CoV-2 variants through development of vaccines and therapeutics. <i>Frontiers in Materials</i> , 0, 9, .	1.2	0
655	What is the role of aerosol transmission in SARS-Cov-2 Omicron spread in Shanghai?. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	14
656	Influence and Control of SARS-CoV-2 Transmission under Two Different Models. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 11849.	1.3	0
657	Advancing disease genomics beyond COVID-19 and reducing health disparities: what does the future hold for Africa?. <i>Briefings in Functional Genomics</i> , 0, , .	1.3	1
659	Replacement dynamics and the pathogenesis of the Alpha, Delta and Omicron variants of SARS-CoV-2. <i>Epidemiology and Infection</i> , 2023, 151, .	1.0	3
660	Challenges and developments in universal vaccine design against SARS-CoV-2 variants. <i>Npj Vaccines</i> , 2022, 7, .	2.9	25
664	The current progress in the use of boron as a platform for novel antiviral drug design. <i>Expert Opinion on Drug Discovery</i> , 0, , 1-12.	2.5	0

#	ARTICLE	IF	CITATIONS
665	SARS-CoV-2 vaccination-infection pattern imprints and diversifies T cell differentiation and neutralizing response against Omicron subvariants. <i>Cell Discovery</i> , 2022, 8, .	3.1	3
666	Clinical severity of Omicron subvariants BA.1, BA.2, and BA.5 in a population-based cohort study in British Columbia, Canada. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	13
668	Advancing detection and response capacities for emerging and re-emerging pathogens in Africa. <i>Lancet Infectious Diseases</i> , The, 2023, 23, e185-e189.	4.6	4
669	Progress Update on the Epidemiology of COVID-19 Variants and the Assessment Status of Developed Vaccines. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2022, 13, 293-299.	0.2	0
670	Guest edited collection serological study of SARS-CoV-2 antibodies in Japanese cats using protein-A/G-based ELISA. <i>BMC Veterinary Research</i> , 2022, 18, .	0.7	1
671	Contributions of adaptation and purifying selection to SARS-CoV-2 evolution. <i>Virus Evolution</i> , 2022, 8, .	2.2	30
672	AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants. <i>European Journal of Cancer</i> , 2023, 181, 102-118.	1.3	2
673	Bayesian Molecular Dating Analyses Combined with Mutational Profiling Suggest an Independent Origin and Evolution of SARS-CoV-2 Omicron BA.1 and BA.2 Sub-Lineages. <i>Viruses</i> , 2022, 14, 2764.	1.5	2
674	Genome Evolution and Early Introductions of the SARS-CoV-2 Omicron Variant in Mexico. <i>Virus Evolution</i> , 2022, 8, .	2.2	3
675	Dynamics of anti-spike IgG antibody after a third BNT162b2 COVID-19 vaccination in Japanese health care workers. <i>Heliyon</i> , 2022, 8, e12125.	1.4	3
676	Neutralizing and enhancing antibodies against SARS-CoV-2. <i>Inflammation and Regeneration</i> , 2022, 42, .	1.5	6
677	SARS-CoV-2 Africa dashboard for real-time COVID-19 information. <i>Nature Microbiology</i> , 2023, 8, 1-4.	5.9	7
678	Comparing Prospective Incident Severe Acute Respiratory Syndrome Coronavirus 2 Infection Rates During Successive Waves of Delta and Omicron in Johannesburg, South Africa. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	0
679	A bias of Asparagine to Lysine mutations in SARS-CoV-2 outside the receptor binding domain affects protein flexibility. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
680	Severity of COVID-19 among Hospitalized Patients: Omicron Remains a Severe Threat for Immunocompromised Hosts. <i>Viruses</i> , 2022, 14, 2736.	1.5	10
681	Modified DNA vaccine confers improved humoral immune response and effective virus protection against SARS-CoV-2 delta variant. <i>Scientific Reports</i> , 2022, 12, .	1.6	5
682	A biophysical model of viral escape from polyclonal antibodies. <i>Virus Evolution</i> , 2022, 8, .	2.2	16
683	Rapid Evaluation of the Xpert® Xpress CoV-2 plus and Xpert® Xpress CoV-2/Flu/RSV plus Tests. <i>Diagnostics</i> , 2023, 13, 34.	1.3	5

#	ARTICLE	IF	CITATIONS
684	Antibody-dependent cellular cytotoxicity against SARS-CoV-2 Omicron sub-lineages is reduced in convalescent sera regardless of infecting variant. <i>Cell Reports Medicine</i> , 2023, 4, 100910.	3.3	5
685	ViralVar: A Web Tool for Multilevel Visualization of SARS-CoV-2 Genomes. <i>Viruses</i> , 2022, 14, 2714.	1.5	3
686	Bayesian SIR model with change points with application to the Omicron wave in Singapore. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
687	Modelling the dynamics of infection, waning of immunity and re-infection with the Omicron variant of SARS-CoV-2 in Aotearoa New Zealand. <i>Epidemics</i> , 2022, 41, 100657.	1.5	10
688	The humoral and cellular immune evasion of SARS-CoV-2 Omicron and sub-lineages. <i>Virologica Sinica</i> , 2022, 37, 786-795.	1.2	12
689	Recent developments in the immunopathology of COVID-19. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2023, 78, 369-388.	2.7	33
690	Origin and Reversion of Omicron Core Mutations in the Evolution of SARS-CoV-2 Genomes. <i>Viruses</i> , 2023, 15, 30.	1.5	3
691	Neurological complications of COVID-19. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2023, 116, 161-180.	0.2	8
693	Alpha and Omicron SARS-CoV-2 Adaptation in an Upper Respiratory Tract Model. <i>Viruses</i> , 2023, 15, 13.	1.5	1
694	Impact of SARS-CoV-2 exposure history on the T _H cell and IgG response. <i>Cell Reports Medicine</i> , 2023, 4, 100898.	3.3	13
696	The Omicron variant wave: Where are we now and what are the prospects?. <i>Journal of the Chinese Medical Association</i> , 2023, 86, 135-137.	0.6	4
697	Retrospective Modeling of the Omicron Epidemic in Shanghai, China: Exploring the Timing and Performance of Control Measures. <i>Tropical Medicine and Infectious Disease</i> , 2023, 8, 39.	0.9	7
698	Bivalent intra-spike binding provides durability against emergent Omicron lineages: Results from a global consortium. <i>Cell Reports</i> , 2023, 42, 112014.	2.9	11
699	Immunity against Delta and Omicron variants elicited by homologous inactivated vaccine booster in kidney transplant recipients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
700	Baseline Sequencing Surveillance of Public Clinical Testing, Hospitals, and Community Wastewater Reveals Rapid Emergence of SARS-CoV-2 Omicron Variant of Concern in Arizona, USA. <i>MBio</i> , 2023, 14, .	1.8	5
701	Impact of Reinfection with SARS-CoV-2 Omicron Variants in Previously Infected Hamsters. <i>Journal of Virology</i> , 0, , .	1.5	4
702	Determinants and Mechanisms of the Low Fusogenicity and High Dependence on Endosomal Entry of Omicron Subvariants. <i>MBio</i> , 2023, 14, .	1.8	14
703	Exploring the binding capacity of lactic acid bacteria derived bacteriocins against RBD of SARS-CoV-2 Omicron variant by molecular simulations. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 10774-10784.	2.0	2

#	ARTICLE	IF	CITATIONS
704	Functionalized Fullerene for Inhibition of SARS-CoV-2 Variants. <i>Small</i> , 2023, 19, .	5.2	8
706	Spike recognition and neutralization of SARS-CoV-2 Omicron subvariants elicited after the third dose of mRNA vaccine. <i>Cell Reports</i> , 2023, 42, 111998.	2.9	15
707	Attenuation and Degeneration of SARS-CoV-2 Despite Adaptive Evolution. <i>Cureus</i> , 2023, , .	0.2	0
708	Infectivity of pseudotyped SARS-CoV-2 variants of concern in different human cell types and inhibitory effects of recombinant spike protein and entry-related cellular factors. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	3
709	Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5. <i>Nature Communications</i> , 2023, 14, .	5.8	54
710	Insight into free energy and dynamic cross-correlations of residue for binding affinity of antibody and receptor binding domain SARS-CoV-2. <i>Heliyon</i> , 2023, 9, e12667.	1.4	0
712	The third vaccine dose significantly reduces susceptibility to the B.1.1.529 (Omicron) SARS-CoV-2 variant. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	3
714	Biparatopic antibody BA7208/7125 effectively neutralizes SARS-CoV-2 variants including Omicron BA.1-BA.5. <i>Cell Discovery</i> , 2023, 9, .	3.1	11
715	Cross-neutralization and viral fitness of SARS-CoV-2 Omicron sublineages. <i>Emerging Microbes and Infections</i> , 2023, 12, .	3.0	11
716	Affinity Exploration of SARS-CoV-2 RBD Variants to mAb-Functionalized Plasmonic Metasurfaces for Label-Free Immunoassay Boosting. <i>ACS Nano</i> , 2023, 17, 3383-3393.	7.3	12
717	Rapidly shifting immunologic landscape and severity of SARS-CoV-2 in the Omicron era in South Africa. <i>Nature Communications</i> , 2023, 14, .	5.8	15
718	Variable number tandem repeats of a 9-base insertion in the N-terminal domain of severe acute respiratory syndrome coronavirus 2 spike gene. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	1
720	Changing Epidemiology of COVID-19 in Children and Adolescents Over Four Successive Epidemic Waves in South Africa, 2020-2022. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2023, 12, 128-134.	0.6	4
721	SARS-CoV-2 diagnostic testing rates determine the sensitivity of genomic surveillance programs. <i>Nature Genetics</i> , 2023, 55, 26-33.	9.4	12
722	SARS-CoV-2 variant biology: immune escape, transmission and fitness. <i>Nature Reviews Microbiology</i> , 0, , .	13.6	160
723	COVID-19 vaccine coverage among college students following vaccine mandates. <i>Journal of American College Health</i> , 0, , 1-5.	0.8	1
724	The impact of cross-reactive immunity on the emergence of SARS-CoV-2 variants. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
725	Omicron B.1.1.529 variant infections associated with severe disease are uncommon in a COVID-19 under-vaccinated, high SARS-CoV-2 seroprevalence population in Malawi. <i>EClinicalMedicine</i> , 2023, 56, 101800.	3.2	2

#	ARTICLE	IF	CITATIONS
726	Potential of green tea EGCG in neutralizing SARS-CoV-2 Omicron variant with greater tropism toward the upper respiratory tract. <i>Trends in Food Science and Technology</i> , 2023, 132, 40-53.	7.8	12
727	COVID-19: A state of art on immunological responses, mutations, and treatment modalities in riposte. <i>Journal of Infection and Public Health</i> , 2023, 16, 233-249.	1.9	7
728	Fingerprinting trimeric SARS-CoV-2 RBD by capillary isoelectric focusing with whole-column imaging detection. <i>Analytical Biochemistry</i> , 2023, 663, 115034.	1.1	3
730	A retrospective study investigating the anxiety and depression level of novel coronavirus Omicron patients in 2022. <i>Medicine (United States)</i> , 2022, 101, e32438.	0.4	0
732	Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants. <i>Genome Medicine</i> , 2022, 14, .	3.6	12
733	WV116 versus Nirmatrelvirâ€™Ritonavir for Oral Treatment of Covid-19. <i>New England Journal of Medicine</i> , 2023, 388, 406-417.	13.9	97
734	Genomic Epidemiology of the SARS-CoV-2 Epidemic in Cyprus from November 2020 to October 2021: The Passage of Waves of Alpha and Delta Variants of Concern. <i>Viruses</i> , 2023, 15, 108.	1.5	3
735	Transitioning the COVID-19 response in the WHO African region: a proposed framework for rethinking and rebuilding health systems. <i>BMJ Global Health</i> , 2022, 7, e010242.	2.0	3
736	Global Infectious Diseases in November 2022: Monthly Analysis. <i>Zoonoses</i> , 2022, 2, .	0.5	0
737	Trends of mismatches in real-time RT-PCR assays developed by the National Institute of Infectious Diseases, Japan for Omicron variants of severe acute respiratory syndrome coronavirus 2. <i>Japanese Journal of Infectious Diseases</i> , 2022, , .	0.5	0
738	Accelerated SARS-CoV-2 intrahost evolution leading to distinct genotypes during chronic infection. <i>Cell Reports Medicine</i> , 2023, 4, 100943.	3.3	31
739	Omicron Waves in Argentina: Dynamics of SARS-CoV-2 Lineages BA.1, BA.2 and the Emerging BA.2.12.1 and BA.4/BA.5. <i>Viruses</i> , 2023, 15, 312.	1.5	9
740	Convergent Evolution in SARS-CoV-2 Spike Creates a Variant Soup from Which New COVID-19 Waves Emerge. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2264.	1.8	57
741	Durability of neutralization against Omicron subvariants after vaccination and breakthrough infection. <i>Cell Reports</i> , 2023, 42, 112075.	2.9	5
742	Confronting â€™chaosâ€™™: a qualitative study assessing public health officialsâ€™™ perceptions of the factors affecting Tanzaniaâ€™™s COVID-19 vaccine rollout. <i>BMJ Open</i> , 2023, 13, e065081.	0.8	2
744	A Spike-destructing human antibody effectively neutralizes Omicron-included SARS-CoV-2 variants with therapeutic efficacy. <i>PLoS Pathogens</i> , 2023, 19, e1011085.	2.1	5
745	Characterization of two linear epitopes SARS CoV-2 spike protein formulated in tandem repeat. <i>PLoS ONE</i> , 2023, 18, e0280627.	1.1	2
748	Enhanced cross-recognition of SARS-CoV-2 Omicron variant by peptide vaccine-induced antibodies. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2

#	ARTICLE	IF	CITATIONS
749	Optimization of Population-Level Testing, Contact Tracing, and Isolation in Emerging COVID-19 Outbreaks: a Mathematical Modeling Study of Tonghua City and Beijing Municipality, China, 2021-2022. <i>China CDC Weekly</i> , 2023, 5, 82-89.	1.0	1
750	Kinetics of SARS-CoV-2 neutralizing antibodies in Omicron breakthrough cases with inactivated vaccination: Role in inferring the history and duration of infection. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
751	Coronavirus Immunotherapeutic Consortium Database. Database: the Journal of Biological Databases and Curation, 2023, 2023, .	1.4	4
752	Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages. <i>Scientific Reports</i> , 2023, 13, .	1.6	26
753	Mathematical modelling of the waning of anti-RBD IgG SARS-CoV-2 antibody titers after a two-dose BNT162b2 mRNA vaccination. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
754	Retrospective Insights of the COVID-19 Epidemic in the Major Latin American City, São Paulo, Southeastern Brazil. <i>Viruses</i> , 2023, 15, 327.	1.5	0
756	Evaluation of the Rapid Antigen Detection Test for Diagnosing SARS-CoV-2 during the COVID-19 Pandemic: Experience from a Centralized Isolation Site in Shanghai, China. <i>Microbiology Spectrum</i> , 2023, 11, .	1.2	2
757	Monitoring algorithm of hospitalized patients in a medical center with SARS-CoV-2 (Omicron variant) infection: clinical epidemiological surveillance and immunological assessment. <i>PeerJ</i> , 0, 11, e14666.	0.9	0
758	PCIF1-mediated deposition of 5'-cap N ⁶ ,2'-O-dimethyladenosine in ACE2 and TMPRSS2 mRNA regulates susceptibility to SARS-CoV-2 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	3.3	8
759	State of the art in epitope mapping and opportunities in COVID-19. <i>Future Science OA</i> , 2023, 9, .	0.9	4
760	SARS-CoV-2 infection and immune responses. <i>AIMS Microbiology</i> , 2023, 9, 245-276.	1.0	2
761	Emergence and spread of two SARS-CoV-2 variants of interest in Nigeria. <i>Nature Communications</i> , 2023, 14, .	5.8	8
762	Clinical performance of rapid antigen tests in comparison to RT-PCR for SARS-CoV-2 diagnosis in Omicron variant: A systematic review and meta-analysis. <i>Reviews in Medical Virology</i> , 2023, 33, .	3.9	13
766	SARS-CoV-2 before and after Omicron: two different viruses and two different diseases?. <i>Journal of Translational Medicine</i> , 2023, 21, .	1.8	9
767	Dynamics of SARS-CoV-2 Antibody Responses up to 9 Months Post-Vaccination in Individuals with Previous SARS-CoV-2 Infection Receiving Inactivated Vaccines. <i>Viruses</i> , 2023, 15, 917.	1.5	1
768	19n01, a broadly neutralizing antibody against omicron BA.1, BA.2, BA.4/5, and other SARS-CoV-2 variants of concern. <i>IScience</i> , 2023, 26, 106562.	1.9	1
769	SARS-CoV-2 Omicron Variant in Medicinal Chemistry Research. <i>Current Topics in Medicinal Chemistry</i> , 2023, 23, .	1.0	1
770	A global aircraft-based wastewater genomic surveillance network for early warning of future pandemics. <i>The Lancet Global Health</i> , 2023, 11, e791-e795.	2.9	9

#	ARTICLE	IF	CITATIONS
771	Inactivated COVID-19 vaccine booster dose shortened the viral shedding time of patients infected with the Omicron variant BA.2. <i>International Journal of Infectious Diseases</i> , 2023, 131, 26-31.	1.5	0
772	Co-occurrence of BA.1 and BA.2 at the start of Singapore's Omicron wave revealed by Community and University Campus wastewater surveillance. <i>Science of the Total Environment</i> , 2023, 875, 162611.	3.9	9
773	TRPC6 inhibitor (BI 764198) to reduce risk and severity of ARDS due to COVID-19: a phase II randomised controlled trial. <i>Thorax</i> , 2023, 78, 816-824.	2.7	3
774	Early Introduction and Community Transmission of SARS-CoV-2 Omicron Variant, New York, New York, USA. <i>Emerging Infectious Diseases</i> , 2023, 29, 371-380.	2.0	1
775	Effectiveness of COVID-19 vaccines against SARS-CoV-2 Omicron variants during two outbreaks from March to May 2022 in Quzhou, China. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	1.4	1
776	Epidemiological, clinical, and household transmission characteristics of children and adolescents infected with SARS-CoV-2 Omicron variant in Shanghai, China: a retrospective, multicenter observational study. <i>International Journal of Infectious Diseases</i> , 2023, 129, 1-9.	1.5	5
777	Insight into SARS-CoV-2 Omicron variant immune escape possibility and variant independent potential therapeutic opportunities. <i>Heliyon</i> , 2023, 9, e13285.	1.4	4
778	Emerging Omicron subvariants evade neutralizing immunity elicited by vaccine or BA.1/BA.2 infection. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	6
779	The Spread of SARS-CoV-2 Omicron Variant in CALABRIA: A Spatio-Temporal Report of Viral Genome Evolution. <i>Viruses</i> , 2023, 15, 408.	1.5	6
780	Modelling the impact of the Omicron BA.5 subvariant in New Zealand. <i>Journal of the Royal Society Interface</i> , 2023, 20, .	1.5	9
781	Modelling Aotearoa New Zealand's COVID-19 protection framework and the transition away from the elimination strategy. <i>Royal Society Open Science</i> , 2023, 10, .	1.1	5
782	Immunogenicity and reactogenicity of heterologous immunization schedules with COVID-19 vaccines: a systematic review and network meta-analysis. <i>Chinese Medical Journal</i> , 2023, 136, 24-33.	0.9	2
783	Clinical Outcomes of Omicron Variant (B.1.1.529) Infection in Children and Adolescents Hospitalized With COVID-19 in Brazil With Observational Data on the Efficacy of the Vaccines in Adolescents. <i>Pediatric Infectious Disease Journal</i> , 2023, 42, 218-225.	1.1	4
785	Impact of Age and Severe Acute Respiratory Syndrome Coronavirus 2 Breakthrough Infection on Humoral Immune Responses After Three Doses of Coronavirus Disease 2019 mRNA Vaccine. <i>Open Forum Infectious Diseases</i> , 2023, 10, .	0.4	0
786	Characterisation of SARS-CoV-2 variants in Beijing during 2022: an epidemiological and phylogenetic analysis. <i>Lancet</i> , The, 2023, 401, 664-672.	6.3	84
787	Combined epidemiology and genetic sequencing surveillance in the era of COVID-19 pandemic; Abu Dhabi experience, United Arab Emirates. <i>Infection, Genetics and Evolution</i> , 2023, 109, 105411.	1.0	2
788	SARS-CoV-2 BA.2 (Omicron) variant infection in pediatric liver transplanted recipients and cohabitants during 2022 Shanghai outbreak: a prospective cohort. <i>Virology Journal</i> , 2023, 20, .	1.4	2
790	The landscape of antibody binding affinity in SARS-CoV-2 Omicron BA.1 evolution. <i>ELife</i> , 0, 12, .	2.8	21

#	ARTICLE	IF	CITATIONS
791	Employing T-Cell Memory to Effectively Target SARS-CoV-2. <i>Pathogens</i> , 2023, 12, 301.	1.2	0
792	Intra-Host Evolution Provides for the Continuous Emergence of SARS-CoV-2 Variants. <i>MBio</i> , 2023, 14, .	1.8	5
793	Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies. <i>Nature Communications</i> , 2023, 14, .	5.8	87
794	Mathematical Modeling of SARS-CoV-2 Omicron Wave under Vaccination Effects. <i>Computation</i> , 2023, 11, 36.	1.0	9
795	Age-dependent impairment in antibody responses elicited by a homologous CoronaVac booster dose. <i>Science Translational Medicine</i> , 2023, 15, .	5.8	9
796	Dynamics of SARS-CoV-2 VOC Neutralization and Novel mAb Reveal Protection against Omicron. <i>Viruses</i> , 2023, 15, 530.	1.5	1
798	O-Linked Sialoglycans Modulate the Proteolysis of SARS-CoV-2 Spike and Likely Contribute to the Mutational Trajectory in Variants of Concern. <i>ACS Central Science</i> , 2023, 9, 393-404.	5.3	8
799	Origin and evolution of SARS-CoV-2. <i>European Physical Journal Plus</i> , 2023, 138, .	1.2	16
800	Computational pipeline provides mechanistic understanding of Omicron variant of concern neutralizing engineered ACE2 receptor traps. <i>Structure</i> , 2023, 31, 253-264.e6.	1.6	3
801	Dynamics of Early Establishment of SARS-CoV-2 VOC Omicron Lineages in Minas Gerais, Brazil. <i>Viruses</i> , 2023, 15, 585.	1.5	2
802	When to update COVID-19 vaccine composition. <i>Nature Medicine</i> , 2023, 29, 776-780.	15.2	9
803	Vaccine- and Breakthrough Infection-Elicited Pre-Omicron Immunity More Effectively Neutralizes Omicron BA.1, BA.2, BA.4 and BA.5 Than Pre-Omicron Infection Alone. <i>Current Issues in Molecular Biology</i> , 2023, 45, 1741-1761.	1.0	2
805	Sustained Low Incidence of Severe and Fatal COVID-19 Following Widespread Infection Induced Immunity after the Omicron (BA.1) Dominant in Gauteng, South Africa: An Observational Study. <i>Viruses</i> , 2023, 15, 597.	1.5	7
806	Combined Use of RT-qPCR and NGS for Identification and Surveillance of SARS-CoV-2 Variants of Concern in Residual Clinical Laboratory Samples in Miami-Dade County, Florida. <i>Viruses</i> , 2023, 15, 593.	1.5	2
807	Viral Lineages in the 2022 RSV Surge in the United States. <i>New England Journal of Medicine</i> , 2023, 388, 1335-1337.	13.9	24
808	Glycan masking of a non-neutralising epitope enhances neutralising antibodies targeting the RBD of SARS-CoV-2 and its variants. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	4
809	Outbreak.info genomic reports: scalable and dynamic surveillance of SARS-CoV-2 variants and mutations. <i>Nature Methods</i> , 2023, 20, 512-522.	9.0	111
810	Dynamic Changes of ORF1ab and N Gene Ct Values in COVID-19 Omicron Inpatients of Different Age Groups in Beijing Municipality, China, November-December 2022. <i>China CDC Weekly</i> , 2023, 5, 180-183.	1.0	2

#	ARTICLE	IF	CITATIONS
811	Epidemiological features, genomic characteristics, and origin tracing of the COVID-19 outbreaks in Beijing from January to September 2022. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	0
812	COVID-19 mRNA vaccine protects against SARS-CoV-2 Omicron BA.1 infection in diet-induced obese mice through boosting host innate antiviral responses. <i>EBioMedicine</i> , 2023, 89, 104485.	2.7	4
813	Value of Laboratory Indicators in Predicting Pneumonia in Symptomatic COVID-19 Patients Infected with the SARS-CoV-2 Omicron Variant. <i>Infection and Drug Resistance</i> , 0, Volume 16, 1159-1170.	1.1	4
815	Safety and incidence of COVID-19 following ChAdOx1(AZD1222) COVID-19 vaccination in Botswana. <i>Journal of Infection</i> , 2023, , .	1.7	1
816	Global Dynamics of Porcine Enteric Coronavirus PEDV <i>Epidemiology, Evolution, and Transmission. Molecular Biology and Evolution</i> , 2023, 40, .	3.5	22
817	Comparison of SARS-CoV-2 Detection in Nasopharyngeal Swab and Saliva Samples from Patients Infected with Omicron Variant. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4847.	1.8	4
818	CRISPR techniques and potential for the detection and discrimination of SARS-CoV-2 variants of concern. <i>TrAC - Trends in Analytical Chemistry</i> , 2023, 161, 117000.	5.8	11
819	Immune evasion of neutralizing antibodies by SARS-CoV-2 Omicron. <i>Cytokine and Growth Factor Reviews</i> , 2023, 70, 13-25.	3.2	17
820	Genomic epidemiology of SARS-CoV-2 during the first four waves in Mozambique. <i>PLOS Global Public Health</i> , 2023, 3, e0001593.	0.5	1
821	Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron Subvariants. <i>Microbiology Spectrum</i> , 2023, 11, .	1.2	5
822	Toward a global virus genomic surveillance network. <i>Cell Host and Microbe</i> , 2023, 31, 861-873.	5.1	13
823	Real-World COVID-19 Vaccine Protection Rates against Infection in the Delta and Omicron Eras. <i>Research</i> , 2023, 6, .	2.8	0
824	Impact of inactivated vaccines on decrease of viral RNA levels in individuals with the SARS-CoV-2 Omicron (BA.2) variant: A retrospective cohort study in Shanghai, China. <i>Frontiers in Public Health</i> , 0, 11, .	1.3	2
825	Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the SARS-CoV-2 Omicron BA.1 and BA.2 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS). <i>Expert Review of Vaccines</i> , 2023, 22, 288-298.	2.0	4
826	Molecular Epidemiology and Diversity of SARS-CoV-2 in Ethiopia, 2020-2022. <i>Genes</i> , 2023, 14, 705.	1.0	2
827	Seasonal effects decouple SARS-CoV-2 haplotypes worldwide. <i>F1000Research</i> , 0, 12, 267.	0.8	4
828	Transmission of SARS-CoV-2 Omicron Variant under a Dynamic Clearance Strategy in Shandong, China. <i>Microbiology Spectrum</i> , 2023, 11, .	1.2	2
829	Comparative complete scheme and booster effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infections with SARS-CoV-2 Omicron (BA.1) and Delta (B.1.617.2) variants: A case-case study based on electronic health records. <i>Influenza and Other Respiratory Viruses</i> , 2023, 17, .	1.5	0

#	ARTICLE	IF	CITATIONS
830	The changing health impact of vaccines in the COVID-19 pandemic: A modeling study. <i>Cell Reports</i> , 2023, 42, 112308.	2.9	1
832	Deep Structural Analysis of Myriads of Omicron Sub-Variants Revealed Hotspot for Vaccine Escape Immunity. <i>Vaccines</i> , 2023, 11, 668.	2.1	3
833	Evaluation of antibody kinetics and durability in healthy individuals vaccinated with inactivated COVID-19 vaccine (CoronaVac): A cross-sectional and cohort study in Zhejiang, China. <i>ELife</i> , 0, 12, .	2.8	5
835	Retrospective Analysis of the Effectiveness of Remdesivir in COVID-19 Treatment during Periods Dominated by Delta and Omicron SARS-CoV-2 Variants in Clinical Settings. <i>Journal of Clinical Medicine</i> , 2023, 12, 2371.	1.0	2
837	Impact of hybrid immunity booster vaccination and Omicron breakthrough infection on SARS-CoV-2 VOCs cross-neutralization. <i>IScience</i> , 2023, 26, 106457.	1.9	3
838	Characteristics and Occurrence Scenarios of Staff Exposed to SARS-CoV-2 Omicron in Shanghai Lingang Fangcang Shelter Hospital, CHINA. <i>Infection and Drug Resistance</i> , 0, Volume 16, 1619-1628.	1.1	0
839	Host protection against Omicron BA.2.2 sublineages by prior vaccination in spring 2022 COVID-19 outbreak in Shanghai. <i>Frontiers of Medicine</i> , 2023, 17, 562-575.	1.5	8
840	Association of SARS-CoV-2 BA.4/BA.5 Omicron lineages with immune escape and clinical outcome. <i>Nature Communications</i> , 2023, 14, .	5.8	17
841	Analysis of well-annotated next-generation sequencing data reveals increasing cases of SARS-CoV-2 reinfection with Omicron. <i>Communications Biology</i> , 2023, 6, .	2.0	8
842	Effectiveness of BNT162b2 and CoronaVac vaccines against omicron in children aged 5 to 11Âyears. <i>World Journal of Pediatrics</i> , 2023, 19, 949-960.	0.8	2
843	Humoral and T Cell Immune Responses against SARS-CoV-2 after Primary and Homologous or Heterologous Booster Vaccinations and Breakthrough Infection: A Longitudinal Cohort Study in Malaysia. <i>Viruses</i> , 2023, 15, 844.	1.5	3
844	Nonsystematic Reporting Biases of the SARS-CoV-2 Variant Mu Could Impact Our Understanding of the Epidemiological Dynamics of Emerging Variants. <i>Genome Biology and Evolution</i> , 2023, 15, .	1.1	1
845	The Isolation and In Vitro Differentiation of Primary Fetal Baboon Tracheal Epithelial Cells for the Study of SARS-CoV-2 Host-Virus Interactions. <i>Viruses</i> , 2023, 15, 862.	1.5	2
846	Tracking the Genomic Evolution of SARS-CoV-2 for 29 Months in South Korea. <i>Viruses</i> , 2023, 15, 873.	1.5	3
847	The Omicron Lineages BA.1 and BA.2 (Betacoronavirus SARS-CoV-2) Have Repeatedly Entered Brazil through a Single Dispersal Hub. <i>Viruses</i> , 2023, 15, 888.	1.5	4
848	Humoral and cellular immunity in three different types of COVID-19 vaccines against SARS-CoV-2 variants in a real-world data analysis. <i>Journal of Microbiology, Immunology and Infection</i> , 2023, 56, 705-717.	1.5	6
849	High-throughput sequencing approaches applied to SARS-CoV-2. <i>Wellcome Open Research</i> , 0, 8, 150.	0.9	0
851	Mechanism of a rabbit monoclonal antibody broadly neutralizing SARS-CoV-2 variants. <i>Communications Biology</i> , 2023, 6, .	2.0	2

#	ARTICLE	IF	CITATIONS
852	Redistribution and Activation of CD16brightCD56dim NK Cell Subset to Fight against Omicron Subvariant BA.2 after COVID-19 Vaccination. <i>Microorganisms</i> , 2023, 11, 940.	1.6	1
853	The evolution of SARS-CoV-2. <i>Nature Reviews Microbiology</i> , 2023, 21, 361-379.	13.6	239
854	Germline-encoded amino acid-binding motifs drive immunodominant public antibody responses. <i>Science</i> , 2023, 380, .	6.0	28
855	COVID-19 infection after SARS-CoV-2 mRNA vaccination in Multiple Sclerosis, AQP4-antibody NMOSD and MOGAD patients during the Omicron subvariant BA.1/2 wave in Singapore. <i>Journal of Neurology</i> , 2023, 270, 2817-2825.	1.8	3
856	Booster with Ad26.COVS or Omicron-adapted vaccine enhanced immunity and efficacy against SARS-CoV-2 Omicron in macaques. <i>Nature Communications</i> , 2023, 14, .	5.8	10
857	Multiplex RT Real-Time PCR Based on Target Failure to Detect and Identify Different Variants of SARS-CoV-2: A Feasible Method That Can Be Applied in Clinical Laboratories. <i>Diagnostics</i> , 2023, 13, 1364.	1.3	1
858	Suramin binds and inhibits infection of SARS-CoV-2 through both spike protein-heparan sulfate and ACE2 receptor interactions. <i>Communications Biology</i> , 2023, 6, .	2.0	4
859	Potent Omicron-neutralizing antibodies isolated from a patient vaccinated 6 months before Omicron emergence. <i>Cell Reports</i> , 2023, 42, 112421.	2.9	3
860	Non-spike and spike-specific memory T cell responses after the third dose of inactivated COVID-19 vaccine. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	4
861	Comparative epidemic expansion of SARS-CoV-2 variants Delta and Omicron in the Brazilian State of Amazonas. <i>Nature Communications</i> , 2023, 14, .	5.8	5
862	Prediction models for neutralization activity against emerging SARS-CoV-2 variants: A cross-sectional study. <i>Frontiers in Microbiology</i> , 0, 14, .	1.5	3
864	Human airway and nasal organoids reveal escalating replicative fitness of SARS-CoV-2 emerging variants. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	3.3	16
865	Temporal dynamics and fatality of SARS-CoV-2 variants in Bangladesh. <i>Health Science Reports</i> , 2023, 6, .	0.6	0
866	Characteristics and outcomes of COVID-19 patients during the BA.5 omicron wave in Tehran, Iran: a prospective observational study. <i>BMC Infectious Diseases</i> , 2023, 23, .	1.3	1
867	Variant-specific introduction and dispersal dynamics of SARS-CoV-2 in New York City from Alpha to Omicron. <i>PLoS Pathogens</i> , 2023, 19, e1011348.	2.1	3
868	COVID-19 as a catalyst for reimagining cervical cancer prevention. <i>ELife</i> , 0, 12, .	2.8	1
869	BBIBP-CorV vaccination accelerates anti-viral antibody responses in heterologous Omicron infection: A retrospective observation study in Shanghai. <i>Vaccine</i> , 2023, , .	1.7	2
871	Large Diffusion of Severe Acute Respiratory Syndrome Coronavirus 2 After the Successive Epidemiological Waves, Including Omicron, in Guinea and Cameroon: Implications for Vaccine Strategies. <i>Open Forum Infectious Diseases</i> , 2023, 10, .	0.4	2

#	ARTICLE	IF	CITATIONS
872	Toward a pan-SARS-CoV-2 vaccine targeting conserved epitopes on spike and non-spike proteins for potent, broad and durable immune responses. <i>PLoS Pathogens</i> , 2023, 19, e1010870.	2.1	11
873	Epidemiological Surveillance Reveals the Rise and Establishment of the Omicron SARS-CoV-2 Variant in Brazil. <i>Viruses</i> , 2023, 15, 1017.	1.5	2
874	mRNA-1273 boost after BNT162b2 vaccination generates comparable SARS-CoV-2-specific functional responses in naïve and COVID-19-recovered individuals. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
932	Case report: Acute hepatitis in neonates with COVID-19 during the Omicron SARS-CoV-2 variant wave: a report of four cases. <i>Frontiers in Pediatrics</i> , 0, 11, .	0.9	0
1011	SARS-CoV-2 evolution in the Omicron era. <i>Nature Microbiology</i> , 2023, 8, 1952-1959.	5.9	18
1060	B-cell and antibody responses to SARS-CoV-2: infection, vaccination, and hybrid immunity. , 2024, 21, 144-158.		4
1066	SARS-CoV-2 and innate immunity: the good, the bad, and the "goldilocks", 2024, 21, 171-183.		4
1123	Molecular biology of SARS-CoV-2 and techniques of diagnosis and surveillance. <i>Advances in Clinical Chemistry</i> , 2023, , .	1.8	0
1141	Pathogen evolution, prevention/control strategy and clinical features of COVID-19: experiences from China. <i>Frontiers of Medicine</i> , 2023, 17, 1030-1046.	1.5	0
1143	Epidemiology of COVID-19. <i>Progress in Molecular Biology and Translational Science</i> , 2024, , .	0.9	0
1151	Small-molecule anti-COVID-19 drugs and a focus on China's homegrown mindeudesivir (VV116). <i>Frontiers of Medicine</i> , 2023, 17, 1068-1079.	1.5	1
1153	EG.5 (Eris) and BA.2.86 (Pirola) two new subvariants of SARS-CoV-2: a new face of old COVID-19. <i>Infection</i> , 2024, 52, 337-343.	2.3	1
1155	SARS-CoV-2 variant biology and immune evasion. <i>Progress in Molecular Biology and Translational Science</i> , 2024, , 45-66.	0.9	0
1157	Comparative Perspective of Evolution of SARS-CoV-2 and 1918 Influenza Virus. <i>Journal of Evolutionary Biochemistry and Physiology</i> , 2023, 59, 2022-2032.	0.2	0
1159	Anticipating the future of the COVID-19 pandemic: insights into the emergence of SARS-CoV-2 variant JN.1 and its projected impact on older adults. <i>GeroScience</i> , 2024, 46, 2879-2883.	2.1	2